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Parkinson‘s disease (PD)  is  a chronic, progressive, neurodegenerative 
disorder with currently no known cure.  PD has a significant impact on 
quality of life of the patients, as well as,  the caregivers and family 
members. It  is  the second most common cause of chronic neurological  
disability in US and Europe. According to National Parkinson‘s 
Foundation, there are almost 1 million patients in the Unites States and 
50,000 to 60,000 new cases of  PD are diagnosed each year. The total  
number of  cases of  PD is predicted to double by 2030. The annual cost 
associated with this disease is estimated to be $10.8 billion in the United 
States, including the cost of treatment  and the cost of  the disability.   
Although it  is primarily thought of as  a movement-disorder and is  
clinically diagnosed based on motor symptoms , non-motor symptoms 
such as cognitive and emotional deficits are thought to precede the 
clinical diagnosis  by almost 20 years . By the time of clinical diagnosis ,  
there is  80% loss in the dopamine content in the striatum and 50% 
degeneration of the substantia nigra dopamine cells.  Th e research 
presented in this  thesis was an attempt to develop an animal model of  PD  
in its pre-motor stages. Such a model  would allow us to develop pre-
clinical  markers for PD, and facil itate the development and testing of  
potential treatment strategies for the non -motor symptoms of the 
disorder.  
Specific Aims 
There were five specific aims for this research :  
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  The first specific aim dealt with development of  a rat mo del of PD with 
slow, progressive onset of motor deficits ,  determination of timeline for 
future studies, and quantif ication the dopamine depletion in this 
model at a pre-motor stage.   
  The second and the third specific  aims focused on testing for 
emotional (aversion) deficits  and cognitive (executive functioning) 
deficits in this rat model at the 3 week timepoint determined during 
specific aim 1.   
  The fourth specific aim was to determine the brain network changes 
associated with the behavioral changes observ ed our rat model using 
resting state connectivity as a measure.  
  The fifth and the final specif ic aim was to test sodium butyrate, a drug 
from the histone deacetylase inhibitor family,  as  a potential treatment  
option for cognitive deficits in PD.  
Results 
The 6-hydroxy dopamine based stepwise striatal lesion model of pre-
motor PD, developed during this research , exhibits delayed onset of  
Parkinsonian gait  l ike symptoms by week 4 after the lesions. At 3  weeks 
post lesion (3WKPD), the rats exhibit 27% reduction in striatal dopamine 
and 23%reduction in substantia nigra dopamine cells ,  with lack of any 
apparent motor deficits .  The 3WKPD rats also exhibited changes in 
aversion.  The fMRI study with the aversive scent pointed towards 
possible amygdala dysfunction subserving the aversion deficits.  The  
executive function deficits tested using a rat analog of the Wisconsin card 
sorting test,  divulged an extra-dimensional set shifting deficit  in the 
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3WKPD rats similar  to those reported in PD patients. The resting state 
connectivity study indicated significant changes in the 3WKPD rats 
compared to age matched controls.   We observed increased overall  
connectivity of the motor cortex  and increased CPu connectivity with 
prefrontal cortex, cingulate cortex, and hypothalamus in the 3WKPD rats 
compared to the controls.  These observations parallel the observations in 
unmedicated early-stage PD patients .  We also observed negative 
correlation between amygdala and prefrontal cortex as reported in 
humans. This  negative correlation was lost in 3WKPD rats.   
Sodium butyrate treatment , tested in the cognitive deficit  study , was 
able to ameliorate the extra -dimensional set  shifting deficit  observed in 
this model.  This treatment also improved the attentional set  formation.  
Conclusion 
Taken together, our observations indicate that,  the model of pre -motor 
stage PD developed during this research is a very high face validity rat  
model of late Braak stage 2 or early Braak stage 3 PD.  Sodium butyrate 
was able to alleviate the cognitive deficits obs erved in our rat model.   
Hence, along with the prior reports of anti -depressant and 
neuroprotective effects of this drug, our results point towards a possible 
treatment strategy for the non-motor deficits of PD.   
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Chapter 1. Introduction 
Motivation 
Parkinson‘s disease (PD) is a progressive neurodegenerative disorder 
that eventually leads to the patient being completely bed or chair bound 
and needing complete assistance. It  affects 1 -2% of the population over 65 
years of age, making it  the second most prevalent neurode generative 
disorder. There are almost 1 mill ion patients in the Unites States alone;  
with 50,000 to 60,000 new cases of PD are diagnosed each year . The total  
number of cases of  PD is predicted to double by the year 20 30. The 
annual cost associated with this disease is estimated to be $10.8 billion in 
the United States (Chen, 2010; O‘Brien et al. ,  2009) .  This cost includes,  
not just the cost of treatment of this disease, but also the cost of the 
disability that follows it.  This is a chronic progressive disorder and has a 
significant impact on quality of  l ife of the patients, as  well as,  the 
caregivers and family members (Chen,  2010).  
Predominantly  thought of as  a motor disorder of the elderly, PD has also 
been known to have young and juvenile  onsets starting at,  as  early as,  20 
years of age. Exact causes of this disease are unknown . Most of the PD 
cases are thought to be idiopathic cases, but a combination of genetic  
mutations and exposure to environmental toxins  are implicated in 
increasing an individual‘s risk. Currently known genes  that are linked to 
PD, make up less than 20% of the total PD cases. In the 19 80s, self  
administration of  a contaminant of heroin, a drug of abuse, was l inked to 
development of  symptoms similar to motor symptoms in PD. This led to 
further research into environmental toxins as probable PD causes.  Since 
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then, insecticides, pesticides, herbicides, wood preservatives , or metals 
like manganese and iron have been thought to play a major part in the PD 
etiology.  PD has been shown to have increased prevalence in the rural,  
agricultural or farming regions , or areas with metal processing plan ts.  
Ever since it  was first identified by Dr. James Parkinson‘s in the 1817 as  
‗shaking palsy‘,  PD is still  cl inically diagnosed based on presence of  
motor symptoms like tremors (trembling in hands, arms, legs, jaw, and 
face),  rigidity (stiffness of the l imbs and trunk), bradykinesia (slowness 
of movement) and postural instability (impaired balance and 
coordination). Even though it  is thought of as a movement disorder , a 
variety of co-morbid non-motor symptoms are also reported in the PD 
patients including but not limited to depression, memory  loss and 
executive function deficits,  changes in sense of smell,  deficits in 
recognition of various emotions and sleep disturbances. At the time of 
diagnosis  of PD, there is generally  irreversible damage the substantia 
nigra neurons (~50%) and reduction of  the striatal dopamine (~80%). In 
fact,  the predicted pre-diagnosis phase is thought to date back 5 -20 years  
(Gaig and Tolosa, 2009; Hawkes et al. ,  2010) . In the years prior to the 
onset of motor symptoms and clinical diagnosis,  p atients report  a myriad 
of subtle non-motor deficits,  which if  quantified systematically ,  might 
provide us with the required markers for early detection. However,  the 
problem is that these early signs either go unnoticed or are ― written off‖  
as a part of normal aging. Early detection may enable us to devise 
strategies to prevent further damage. Hence, the motivation behind this 
research was to develop an animal model of pre-motor stage PD, which 
would not have any significant motor deficits,  but would exhibit  s low 
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progressive onset  of  motor symptoms along with non-motor symptoms 
similar to  those seen in  PD. Such a model could then to be used to 
develop behavioral and functional MRI marke rs for the pre-clinical  stage 
of PD. Pre-clinical markers, if  developed, can lead to the early diagnosis 
of patients predisposed to this disease due to genealogy , proximity to 
toxic environments ,  or a combination of both . The advantage of animal  
models is that it  allows us to more precisely control several aspects of a 
study, hence, enabling us to more precisely pin -point the mechanisms 
underlying the observed changes.   
Another reason for development of this  model was that,  the currently 
available drugs and treatment methodologies focus on management of  the 
motor symptoms of PD, and rarely treat the non-motor symptoms. In 
addition, the current drugs  have also been shown to be ineffectual with 
the disease progression. In this research we also attempted  to investigate 
novel treatment methodologies for alleviating the non-motor symptoms of 
PD. 
Thesis outline 
We begin with a discussion of Parkinson‘s disease, its  scope  of 
occurrence,  and statistics within the population in Chapter 2. This  
chapter discusses history and etiology of Parkinson‘s disease, and its  
genetic and environmental causes . This discussion continues with clinical  
diagnostic  methods and clinically recognized symptomology. The chapter 
ends with a discussion of pre-motor deficits observed in the disease and 
current treatment options available.  
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Chapter 3 provides an overview of  magnetic resonance imaging . Spin 
physics, relaxation times, pulse sequences, and spatial encoding are 
discussed in this  chapter. At  the end of  the chapter , the application of  
MRI in functional imaging of the brain is  introduced.  
Chapter 4 outlines the animal model devised for this study and its 
characterization with respect to motor deficits and immuno-
histochemostry.  
Chapter 5 describes our findings of  aversion changes in this model of  
per-motor PD. This chapter  also describes our results  supporting possible 
deficits in response generation as observed in the funct ional MRI study.  
Chapter 6 presents the executive functioning deficits observed in this 
rat model.  Sodium butyrate treatment seem s to mitigate the deleterious 
effects of 6-OHDA and may also have additional cognition enhancing 
effects.  
Chapter 7 discusses resting state functional MRI as a technique to 
observe connectivity changes in the brain as a result  of dopamine 
depletion and treatment . The results of this study agree with the findings 
reported in patients with PD. 
Finally,  Chapter 8 & Chapter 9 present the comprehensive summary and 
future directions for this research.   
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Chapter 2. Parkinson’s disease 
History 
Written documentation of  PD can be found in  ancient literatures as old 
as the Ayrveda, an ancient Indian text thought to have been in existence 
since 5000 BC, where PD is referred to as  ‗Kamp Vata‘,  translated 
literally as shaking palsy. There are additional references of this disorder 
in Chinese medical texts (500 B.C.) ,  as  well as,  in ancient Roman and 
Greek writings. In the more recent times, a 
London based physician,  James Parkinson, 
was the to first describe Parkinson‘s disease 
or ‗shaking palsy‘ ,  as it  was then referred to 
as,  in his publicat ion called ‗An essay on the 
Shaking Palsy ‘  (Parkinson, 1817) . He 
described the disorder  as ―Involuntary 
tremulous motion,  with lessened muscular 
power, in parts not in action and even when 
supported; with a propensity to bend the 
trunk forwards, and to pass from a walking to a running pace: the senses 
and intellects being uninjured.‖  (Parkinson, 1817)  In this thesis ,  he goes 
on to describe the subtle onset of the motor deficits and their subsequent 
progression, based on his observations of  different subjects  on the streets  
of London. Identifying it  as a disease separate from ordinary Palsy,  
Parkinson differentiated shaking palsy  from paralysis of  certain body 
parts which might be accompanied by tremors. In 1828, Wilhelm van 
Humboldt, a philosopher and diplomat,  described in a letter ,  his own 
Figure 1: Sir W. R. Grower’s 
Parkinson’s disease sketch 
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symptoms PD, which included micrographia, akinesia and changes in 
posture (Hindle, 2008). In 1861 and 1862, Jean-Martin Charcot and 
Alfred Vulpian added the mask face (characteristic expressionless face  
observed in PD patients),  contractions of hands and feet ,  and rigidity to 
the list of symptoms. In addition to expanding the symptom list,  Charcot 
finally renamed the shaking palsy as  Parkinson‘s disease ,  in memory of 
Dr. James Parkinson (Hindle,  2008).  
Demographics 
PD is the second most common cause of chronic neurological  disability 
in the US and Europe. 1 -2% of people over 65 years of age have PD. 
According to the National Parkinson‘s Foundation ,  50,000-60,000 new 
cases of PD are diagnosed each year in the United States and the 
demographic trends predict that the number of patients will double by the 
year 2030 (Chen,  2010; O‘Brien et  al. ,  2009) .  Dependent upon the age of 
the patient  at  disease onset,  PD is  classified as either juvenile-onset PD 
(<20years),  early-onset PD (<50 years),  or late-onset PD (>50 years).  
Etiology of Parkinson’s disease 
The exact etiology of PD is not completely understood. The known 
causes of PD include genetics ,  environmental causes,  or a combination of  
the two (Abou-Sleiman et al. ,  2006; Di Monte et al . ,  2002; Goldberg et  
al. ,  2003; Liu and Yang, 2005; Perez and Palmiter,  2005; Schapira, 2006; 
Steece-Collier  et  al. ,  2002; Vlajinac et al. ,  2010) .  
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Genetics of PD 
Recently,  large scale genetic  studies of families  with a high prevalence 
of PD have led to discovery of a variety of genes linked to PD . Among 
those genes, mutations of SNCA (α-synuclein),  PRKN (parkin), LRRK2 
(Leucine-rich repeat kinase 2),  PINK1 (phosphatase and tensin  
homologue induced protein kinase 1)  and DJ-1 (also known as PARK7 or 
Parkinson‘s  disease (autosomal recessive, early onset)  7)  have been 
conclusively proven to cause PD (Bekris et al. ,  2010; Schapira, 2009;  
Steece-Collier  et  al. ,  2002) .  
SNCA is a protein expressed routinely throughout the mammalian brain.  
However, over-expression of this  protein has been linked to loss of 
dopaminergic terminals in the striatum, mis -localization and 
accumulation of insoluble SNCA, and motor abnormalit ies  (Fleming et al. ,  
2004; Rockenstein et al. ,  2002) . SNCA is also detected in the lewy bodies 
found in familial ,  as well as,  idiopathic PD (Spillantini  et  al. ,  1997) .  
However,  it  is not understood what the exact role of SNCA is and whether 
the wild type or certain mutations of SNCA lead to development of PD  
(Abou-Sleiman et al . ,  2006) . Variations of SNCA mutation are found in 
early,  as  well  as,  late onset  PD.  
PRKN is an autosomal recessive gene that has been associated heavily 
with cases of  young onset PD. In its normal form, PRKN is essential for  
mitochondrial function, possibly by protecting against  deleterious effects  
of free radicals.  Upon mutation, it  is  thought to cause mitochond rial 
damage and oxidative stress  (Abou-Sleiman et al. ,  2006) . However, 
studies of PRKN mutations in genetic mouse models failed to show the 
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classic dopamine changes observed in PD (Goldberg et al. ,  2003; Perez  
and Palmiter, 2005) . Hence, it  is thought that in PD patients with PRKN 
mutations, an additional environmental insult might be responsib le for 
the reduction in dopamine, with the PRKN mutations increasing one‘s  
vulnerability to those factors . 
Mutations of another autosomal dominant gene, LRRK2 are associated 
with less than 5-6% of familial PD cases.  Hence, only a limited amount of  
post mortem data is available for this gene. Cases with LRRK2 mutation 
are typical of late onset PD. Lewy body pathology and nigrostriatal 
dysfunction, observed in cases with LRRK2 mutations, are indicative of 
idiopathic PD (Abou-Sleiman et al. ,  2006; Bekris et al . ,  2010) . LRRK2‘s 
function in the body is not exactly understood. It  is known to interact  
with other proteins , such as SNCA (Lin et al. ,  2009)  and PRKN (Smith et 
al. ,  2005) which are also associated with PD . 
PINK1 mutations have been reported in PD cases in diverse populations 
across the world including Europeans,  Japanese, Chinese,  Malay and 
Indians. Loss of PINK1 function adversely affects mitochondrial function 
and cell viability under stress. The most active domain in PIN K1 is in its  
kinase domain. The same domain is also the site of many of  the PINK1 
mutations observed in PD. Hence,  it  is believed that  disruption of the 
kinase activity is the disease mechanism in PINK1 mutation involved PD  
(Abou-Sleiman et al. ,  2006) . Additionally,  there are also observations of  
PINK1 mutation in the adenosine triphosphate (ATP) orientation site  
resulting in early onset PD  (Bekris et al. ,  2010) .  
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DJ-1 is a small ubiquitous protein present in neuronal ,  as well as,  glial  
cells.  Down regulation of DJ-1 has been linked to oxidative stress -induced 
cell death. DJ-1 deficient mice are hypersensitive to deleterious effects of  
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a contaminant of a 
drug of abuse known to cause PD (Kim et al. ,  2005) , suggesting DJ-1 
might actively protects cells against apoptosis caused by exposure to 
oxidative stressors.  However,  DJ-1 mutations are quite rare and are found 
in only 1-2% of early onset  PD cases  (Abou-Sleiman et al. ,  2006) . DJ-1 , in 
its mutated form, interacts with PRKN, but in this case PRKN seems to be 
regulating the effects of DJ -1 mutations.  
Hence, most of the genetic mutations related to PD seem to involve 
oxidative stress and mitochondrial dysfunction as the underlying 
mechanisms. There are several other genes that have been identified as 
precursors to PD. Figure 2 describes the pathways following mutation of  
various genes,  that  might ultimately be responsible for cell death in PD.  
Together, all  the known genetic cases make up only a small percentage 
(~20%) of the total PD cases ,  and even fewer can be attributed purely to 
genetic causes (Bekris et al. ,  2010; Schapira, 2006; Steece -Collier et al. ,  
2002). It  is also important to note that the majority of the PD cases , are 
the cases of late onset PD, and are thought to be caused by environmental 
insults,  with genetic factors exacerbating the  effect of  those insults 






―The discovery of Mendelian inherited genes has enhanced our understanding of the pathways that mediate neurodegeneration 
in Parkinson‘s disease. One main pathway of cell toxicity arises through α-synuclein, protein misfolding and aggregation. These 
proteins are ubiquitinated and initially degraded by the ubiquitin–proteasome system (UPS), in which PRKN (parkin) has a 
crucial role. However, there is accumulation and failure of clearance by the UPS over time, which leads to the formation of 
fibrillar aggregates and Lewy bodies. α-Synuclein protofibrils can also be directly toxic, leading to the formation of oxidative 
stress that can further impair the UPS by reducing ATP levels, inhibiting the proteasome, and by oxidatively modifying PRKN. 
This leads to accelerated accumulation of aggregates. Phosphorylation of α-synuclein-containing or tau-containing aggregates 
might have a role in their pathogenicity and formation, but it is not known whether leucine-rich repeat kinase 2 (LRRK2) 
mediates this. Another main pathway is the mitochondrial pathway. There is accumulating evidence for impaired oxidative 
phosphorylation and decreased complex I activity in Parkinson‘s disease, which leads to reactive oxygen species (ROS) 
formation and oxidative stress. In parallel, there is loss of the mitochondrial membrane potential. This leads to opening of the 
mitochondrial permeability transition pore (mPTP), release of cytochrome c from the intermembrane space to the cytosol, and 
activation of mitochondrial-dependent apoptosis resulting in caspase activation and cell death. There is evidence that 
recessive-inherited genes, such as phosphatase and tensin homologue (PTEN)-induced kinase 1 (PINK1), Parkinson‘s disease 
(autosomal recessive, early onset) 7 (DJ1) and HtrA serine peptidase 2 (HTRA2, also known as OMI), might all have 
neuroprotective effects against the development of mitochondrial dysfunction, although the exact site of their action remains 
unknown. PRKN has also been shown to inhibit the release of cytochrome c following ceramide-induced stress, and is itself 
modified by the interacting protein BCL2-associated athanogene 5 (BAG5). Dysfunction of both pathways leads to oxidative 
stress, which causes further dysfunction of these pathways by feedback and feedforward mechanisms, ultimately leading to 
irreversible cellular damage and death. I–IV, mitochondial electron transport chain complexes I–IV; α-syn(PO4)n, phospho-α-
synuclein; A30P, alanine to proline substitution at α-synuclein amino acid residue 30; A53T, alanine to threonine subsitution 
at α-synuclein residue 53; E1, ubiquitin activating enzyme; E2, ubiquitin conjugating enzyme; E46K, glutamic acid to lysine 
substitution at α-synuclein residue 46; NO, nitric oxide; 3n/4n, 3 or 4 copies of α-synuclein; Tau(POi)n, Tau (POi)n, phospho- 
Tau; UCHL1, ubiquitin carboxyl-terminal esterase L1.‖ (Abou-Sleiman et al., 2006) 
Figure 2: Pathways to parkinsonism (Abou-Sleiman et al., 2006). Reprinted with permission. 
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Environmental causes of PD 
In the late 1970s and early 1980s,  self  administration of MPTP, a 
contaminant of drug of abuse, resulted in motor symptoms similar to 
those reported in PD, along with dopamine depletion in the brain 
(Langston and Palfreman, 1995) . This observation led to further 
investigation of  environmental causes such as toxin exposures as a 
contributing factor to PD. A 1996 study in Germany involving 380 PD 
patients and 379 controls ,  reported that exposures to wood preservatives , 
heavy metals  including iron,  zinc and manganese,  or pesticides, had a 
significant correlation with PD development (Seidler  et  al. ,  1996) . 
Pesticide exposure has been shown to increa se incidence of PD to almost 
70% (Ascherio et al. ,  2006) . An epidemiological  study in Denmark 
farmers hospitalized between 1981 and 1993 revealed that workers at 
agricultural and horticultural farms were at significantly higher  risk of 
developing PD (Tuchsen and Jensen,  2000) . A cohort study in Hawaii  
plantations with a 30 year follow up  indicate d that duration of exposures 
to pesticides has a significant correlation to development of PD  
(Petrovitch et al. ,  2002) . Severe short term exposures to pesticides , even 
in residential  settings, has been shown to result in development of PD 
symptoms (Bhatt et al. ,  1999) .  
Additionally,  drinking rural well water  for over 5 years has shown to 
increase the risk of PD development by almost 90% in a California based 
study (Gatto et al. ,  2009) . Researchers from that study believed that the 
observed prevalence  was, in fact,  a result of pesticide contamination of  
the well  water.  A study by Vlajinac et.  at.  links ingestion of well and 
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spring water to PD (Vlajinac et al. ,  2010)  and adds insecticides to the list 
of contributing environmental factors . Another Korean study by Cho et.  
al.  also reports similar findings l inking well water to PD (Cho et al. ,  
2008). Exposure to metals l ike manganese or iron have also been shown 
to produce symptoms similar to the clinical  symptoms of PD  (Willis et  al. ,  
2010). Manganese exposure in industry workers has been shown to mimic 
most of the symptoms of PD, including rest ing tremors, bradykinesia,  
rigidity,  postural instabi lity,  changes in gait,  dystonia and  micrographia 
(Guilarte, 2010). A study of Alabama welders, routinely  exposed to 
welding fumes, revealed a significantly high prevalence of PD among 
welders (Racette et  al. ,  2005) . A recent epidemiological study of 29 
million Medicare beneficiaries by Dr. Willis and colleagues indicated that 
there was a significant correlation between metal emissions and urban 
incidences of PD (Wright Willis et al. ,  2010) . (Figure 3)  
Figure 3: Prevalence of Parkinson's disease in the United States after country level age and race standardization 
(Wright Willis et al., 2010). The color scale indicates the number of Medicare recipients with Parkinson's disease 
for each 100,000. The scale runs from dark green, 1,175 per 100,000, to dark red, 13,800 per 100,000. 
Reproduced as per PubMed Central U.S. fair use guidelines. 
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All in all,  environmental contribution to PD onset is quite significant. 
As mentioned in the previous section, it  is possible that genetic factors 
increase one‘s  vulnerability  to the environmental insults,  hence leading to 
development of PD.  Similar to the observations in genetic PD, 
mitochondria dysfunction is thought to be central to toxin induced PD as 
well.  Mitochondria functioning is essential for cell viability ,  but it  is also 
a site of production of reactive oxygen species (ROS).  ROS are 
chemically-reactive molecules containing oxygen capable of causing 
oxidative stress. Mitochondrial complex I and complex III are known to 
be responsible for keeping these ROS in control.  Environmental  toxins 
are known to inhibit functioning of these complexes , hence leading to 
mitochondria dysfunction and cell death by oxidative stress  (Liu and 
Yang, 2005), leading to the pathology observed in PD .  
PD neuropathology 
The pathology in PD is known to affect the central ,  peripheral,  and the 
entric nervous systems (Braak and Braak, 2000; Hawkes et al. ,  201 0; 
Orimo et al. ,  2005) . It  has been shown to cause substantial  cytoskeletal  
alterations in various brain regions in a slow but relentless manner  
(Kidd, 2000). In addition to being a disorder of the dopamine projection 
system, glutamatergic,  cholinergic,  tryptaminergic,  GABAergic, 
noradrenergic,  and adrenergic damage has also been reported in PD 
(Braak and Braak, 2000) . Hence, the characterization of PD as solely a 
disorder of the dopamine projection system would not be a completely  
accurate statement .  
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Presence of lewy bodies, lewy neuritis,  and dopaminergic degeneration 
are hallmarks of PD pathology , as was f irst demonstrated by F. Lewy in 
1912 (Wakabayashi et al. ,  2006) . Lewy bodies are protein aggregates that,  
among other proteins contain ubiquitin and α -synuclein.  These can 
proteins be found in cell bodies and neurites of certain neuronal 
populations (Lotharius and Brundin, 2002) , including hypothalamus, 
nucleus basalis,  substantia nigra, locus ceruleus, dorsal raphe nucleus 
and dorsal vagal nucleus (Jager and Bethlem, 1960; Kakita et al. ,  1994; 
Ohama and Ikuta,  1976; Oyanagi et al. ,  1990; Wakabayashi and 
Takahashi,  1997) . Lewy bodies have also been reported in the amygdala 
and the cerebral cortex (Braak et  al. ,  1994; Hughes et al. ,  1992) .  
Dopamine pathology in PD is not  homogeneous and not all  
dopaminergic neurons are affected by the pathology of PD. For example,  
severe loss of dopaminergic neurons is reported in the substantia nigra of  
PD patients (Halliday et al. ,  1990) . The striatum, a part of the basal 
ganglia, which receives dopaminergic projections from the substantia 
nigra, is  also significantly impacted by PD (Graybiel et al. ,  1990; Kish et 
al. ,  1988). The striatal damage is more severe in the putamen than in the 
caudate nucleus. The ventral tegmental area is affected to a lesser extent 
as compared to the substantia nigra (Gibb and Lees, 1991) .  The loss of 
dopamine in  the nucleus accumbens is to a much lesser extent, and the 
dopaminergic neurons in the hypothalamus appear to be spared in PD 
(Matzuk and Saper, 1985) .  
The pattern of neuronal damage observed in PD is not random and 
shows specific ity by region, neural cell type,  and has a distinctive 
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bilateral symmetry, which has been noted consistently across postmortem 
studies in patients.  Reasons for the selective degeneration are stil l  
unknown (Braak and Braak,  2000; Braak et al. ,  2003) .  
Diagnosis and clinical symptoms 
James Parkinson originally erroneously asserted that sensory and 
intellectual abilit ies  are unaffected in patients with the disease. Since 
then, the focus has primarily been on the motor aspect of PD 
symptomology.  
Motor symptoms 
According to the National Institute of Neurological Disorders and 
Stroke, the four primary symptoms of PD are  (Weintraub et al. ,  2008):  
1.  Tremor (trembling in hands, arms, legs,  jaw, and face)  
2.  Rigidity (stiffness of  the limbs and trunk)  
3. Bradykinesia (slowness of movement)  
4.  Postural instability ( impaired balance and coordination).   
Along with these there are secondary symptoms which also have been 
reported (Weintraub et  al. ,  2008) .  
  Stooped posture, a tendency to lean forward  
  Dystonia  
  Fatigue  
  Impaired fine motor dexterity and motor coordination  
  Impaired gross motor coordination  
  Poverty of  movement (decreased a rm swing) 
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  Akathisia (feeling of inner restlessness , leading to an inability to 
sit  stil l  or remain motionless)  
  Speech problems,  such as softness of  voice or slurred speech , 
caused by lack of muscle control  
  Loss of facial expression, or "masking"  
  Micrographia (small,  cramped handwriting)  
  Difficulty swallowing  
  Sexual dysfunction  
  Cramping 
  Drooling 
Existence of one or more of the primary symptoms , along with medical 
history of the patient ,  is used to diagnose the disease. Responsiveness to 
Levodopa, one of  the drugs used as a treatment for PD, is also considered 
a confirmation of PD diagnosis.  According to the Hoehn and Yahr scale  
for PD stages (Hoehn and Yahr, 1967) , PD patients go through five stages.  
(Figure 5)  
Stage I:  Very subtle,  unilateral existence of one or more of the 
primary symptoms.  
Stage II:  Bilateral primary symptoms and additional secondary 
symptoms. 
Stage III:  Symptoms from stage two increase in severity ,  and problems 
with balance become prominent. At  this stage, the person with 
Parkinson's  is sti ll  independent.  
20 
 
Stage IV:  Motor symptoms result  in disability,  leading to the patient  
needing assistance in most daily activities.  
Stage V:  Patient is bed or wheelchair bound and needs complete 
assistance.  
Non-motor symptoms of Parkinson’s disease 
Recent reports in PD patients have  confirmed the existence of a variety 
of non-motor symptoms (Bowers et al. ,  2006; Chen, 2010; Cools et al. ,  
2001; Hawkes,  2008; Hawkes et al. ,  1997) . These include:  
  Hyposmia (reported in 80% of the patients at the time of  diagnosis)  
  Pain  
  Cognitive deficits ( about 50%; deficits in memory,  attention, 
executive function and dementia are reported)  
  Sleep disturbances (REM behavior change)  
  Constipation and urinary problems  
  Depression (10 –  40 %) 
  Changes in aversion,  fear and anxiety  
  Compulsive behavior  
  Lack of impulse control  
These non-motor symptoms have been reported by PD patients years 
before the diagnosis.  Currently, the research focus has shifted from the 
motor-symptoms to the non-motor symptoms as they may provide clues 
for pre-motor diagnosis of PD.  
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Pre-motor stages of Parkinson’s disease 
Although the nigrostriatal pathway remains a major focus,  emerging 
information demonstrates the participation of both the mesocortical and 
cortico-limbic pathways in this disease process  (Braak and Braak, 2000) .  
Post-mortem studies have shown existence of lewy bodies and lewy 
neurites, a marker of neurodegeneration, in the olfactory bulb, anterior 
olfactory nucleus, dorsal motor nuclea us complex,  and pons pre-motor 
pathology in PD (Braak et al. ,  2003; Hawkes et al . ,  1997) .  PD patients 
report olfactory deficits years before the clinical diagnosis  (Ponsen et al. ,  
2009) and onset of PD symptoms have shown very strong correlation with 
reports of hyposmia four years before the onset (Ross et  al. ,  2008) . 
Excessive daytime sleepiness (Abbott et al. ,  2005) , depression and 
anxiety (Arabia et  al. ,  2007; Shiba et al. ,  2000)  and constipation 
Figure 4: Tip of iceberg analogy of PD pathology. Reproduced with permission. (Langston, 2006) 
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(Langston, 2006)  are also reported. Langstan refers to the substantia 
nigra symptoms as just the tip of the PD iceberg.  (Figure 4)  
Dopamine depletion is a very pr ominent marker of PD. However,  by the 
time of onset of the motor symptoms in stage I (Hoehn and Yahr scale),  
more than 50% (Fearnley and Lees,  1991; Tang and Eidelberg, 2010)  of  
the substantia nigra dopamine cells  are degenerated and 80% of the 
striatal dopamine is depleted (Fearnley and Lees, 1991; Pahwa and Koller,  
1995; Steece-Collier et al. ,  2002) . Early PD patients show reduction in DA 
tracer uptake in the striatum in contralateral ,  as well as,  ispilateral sides 
while a asymptotic twin study has indicated reduction in striatal DA 
uptake 2-21 years prior to motor symptoms  (Gaig and Tolosa,  2009) .  
Thus, Braak et.  al.  proposed a new timeline  (Hawkes et al. ,  2009)  for 
PD, extending almost 20 years prior to the motor symptoms (Figure 5).   
Braak Stage 1:  Changes in bowel movement (<1 /day), bladder and 
erecti le problems, and changes in olfaction (hyposmia or anosmia) might 
be some of the earliest signs of PD . These changes are accompanied by 
incidental lewy bodies in locus coeruleus , a nucleus in brain stem and 
olfactory pathology.  
Braak Stage 2:  PD patients in this  stage exhibit one or more of the  
following symptoms:  excess daytime sleepiness and REM sleep behavior 
disorder, depression (with serotonergic basis) ,  and obesity. Pathology of  
coeruleus/subcoeruleus complex (CSC),  magnocellular portions of the 
reticular formation, and posterior raphe nuclei  are also observed. Since 
the raphe nucleus is also involved in memory and learning, cognitive 
deficits might be present.   
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Braak Stage 3:  This stage is close to the Hoehn and Yahr stage I .  The 
symptoms include unilateral motor deficits  and depression ( with 
dopaminergic basis) .  Lewy body pathology is observed in the substantia 
nigra and central  nucleus of the amygdala.  Even though Braak et.  al.  do 
not mention it,  given the reports of striatal dopamine depletion observed 
almost 5 years before the onset of motor symptoms, dopamine depletion 
can be added to the pathology of late Braak stage 2 or early Bra ak stage 3.  
Braak Stage 4:  This stage is similar to the Hoehn and Yahr stage II  
with bilateral  motor deficits and  lewy body pathology in multiple sites ,  
including interstitial nucleus of the stria terminalis,  the accessory 
cortical and basolateral nuclei of the amygdala, the ventral claustrum, 
intralaminar nuclei of the thalamus (limbic circuit),  the second sector of  
the Ammon‘s horn and the anteromedial temporal mesocortex. This 
pathology can also be accompanied by changes in impulse control,  
Figure 5: Progression of Parkinson's disease. Reproduced with permission. (Hawkes et al., 2009) 
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hypersexuality and pathological gambling, along with the coexisting 
emotional,  cognitive and olfactory deficits.  
Braak Stages 5 and 6:  These stages are the late stages of PD with 
severe motor deficits,  extensive cortical damage with additional lewy 
body pathology into  the insular,  subgenual mesocortex, anterior cingulate 
regions extending to pre-motor areas of neocortex, primary motor and 
sensory motor areas.  
Treatment  
Currently,  there is no cure available for PD. The most commonly used 
drug is L-3, 4-dihydroxyphenylalanine (Levodopa or L-dopa) (Hauser,  
2010). Unlike dopamine, L-dopa can cross the blood brain barrier when 
given systemically.  Brain enzymes can convert L -dopa to dopamine; thus, 
making it  a good dopamine -replacement therapy. This supplementation of 
dopamine with L-dopa is used to treat the motor symptoms  of PD. Arvid 
Carlsson, a Swedish scientist,  was  the first to show reduction in PD 
symptoms in animals after treatment with L -dopa in the 1950s. He 
demonstrated that dopamine was indeed a neurotransmitter in  the brain, 
and not just a precursor for norepinephrine. Initial trials of L-dopa 
treatment in humans included very low doses of the compound , which 
only produced transient effects.  George Cotzias and his coworkers later 
extended this to the treatment of manganese poisoning and Parkinsonism 
by increasing the dose (Barbeau,  1969; Cotzias, 1968) . Since then, it  is a 
standard treatment for PD. Currently,  i t  is also used in the diagnosis  
process that,  a posit ive response to the L-dopa is considered a 
confirmation of PD. However,  L-dopa treatment is known to  stop working 
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suddenly for short durations from time to  time (Hauser,  2010).  It  is  
prescribed in combination with dopamine deoxylase inhibitor . This 
combination prevents L-dopa‘s synthesis in the blood stream; hence,  
delivering more drug to the brain , reducing some of the side effects  such 
as nausia. Even then, prolonged usage of L -dopa has shown to cause 
motor fluctuations and dyskinesia (spontaneous, involuntary 
movements).  Hence, the start of treatment i s delayed until the PD 
symptoms become severe enough that the benefits outweigh the side 
effects (Hauser, 2010). 
Dopamine agonists can also be prescribed in combination with L -dopa. 
Severe side effects of this treatment  have shown to cause problems such 
as heart valve damage, s leep disorder and impulse co ntrol disorders .  
Anti-cholinergics ,  which decrease the activity of acetylcholine to 
balance out the production of dopamine and acetylcholine ,  can also be 
prescribed during mild PD. This combination has been shown to reduce 
some of the side effects of L -dopa. Adverse effects  of these drugs include 
blurred vision,  dry mouth and urinary retention, and confusion and 
hallucination in older patients.  
MAO-B (monoamine oxydase-B) inhibitors and COMT (catechol -O-
methyl transferase) inhibitors can be prescribed in c onjunction with L-
dopa in order to extend the effectiveness over longer periods of time.  
However,  MAO-B inhibitors may interact with anti -depressants, narcotic 
pain killers  and decongestants  (Hauser, 2010; 
Parkinson'sDiseaseFoundation,  Accessed 2011) .  
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Thus, the available treatments primarily focus on supplementing the 
brain with dopamine, or stimulating the dopamine receptors with 
agonists in an effort to stimulate receptors in absence of dopamine.  
However, after a  few years, most combinations of dopamine treatments 
tend to become less effective, and symptoms become more difficult to 
manage (Rascol et al. ,  2003) . Another important point to note is that ,  
none of these treatments effectively treat  the non -motor symptoms of PD.  
Summary 
Parkinson‘s disease is a progressive neurodegenerative disorder which 
affects various parts of the nervous system in a highly selective and time 
dependent manner,  eventually rendering the patient bed ridden and 
needing complete assistance over time . The exact causes of PD are sti l l  
not completely understood, but genetic predisposal and impact of 
environmental toxins has been heavily l inked to the development of the 
disease. The manifestation of motor deficits,  currently used to diagnose 
PD, occurs relatively late during the progression of the disease. The 
current treatments neither reverse the morphological changes, nor arrest 
the progress of the disease. More research is needed to completely 
understand the pre-motor/pre-diagnosis stages of the disease  and 




Chapter 3. Magnetic Resonance Imaging 
Nuclear Magnetic Resonance to Magnetic Resonance Imaging  
Magnetic resonance imaging (MRI) is based on the principles of nuclear 
magnetic resonance (NMR), which was first described by Isidor Rabi  
during his study of atomic and molecular beam magnetic resonance 
method for observing atomic spectra. Later ,  Felix Bloch and Edward Mills  
Purcell independently applied principles of NMR to solids in 1946  
(Henderson, 1983) .  In 1971, Raymond Damadian established the 
difference between the nuclear relaxation times of tissues and tumors  
(Henderson, 1983) . Paul Lauterbur demonstrated imaging of small test 
tube samples using the principles of NMR in 1973 , using the back 
projection method used in x-ray based computer tomography  (Henderson,  
1983; Lauterbur, 1973) . MRI using phase and frequency encoding and the 
Fourier Transform NMR was first proposed by Richard Ernst in 1975 
(Kumar et al. ,  1975) .  A few years later,  in 1977, Raymond Damadian 
demonstrated a new MRI technique called field-focusing nuclear magnetic 
resonance, and Peter Mansfield developed the echo -planar imaging (EPI)  
technique (Henderson, 1983; Mansfield and Maudsley,  1977) .  In the late 
70s, the word ‗Nuclear‘  had serious negative connotation s attached to it  
and it  was there by dropped from the name and NMRI became MRI. 
Nuclear spin and magnetic dipole moment 
Nuclei of elements are made of positively charged protons and neutral  
neutrons with spins  (Beall et al. ,  1984; Pykett et al. ,  1982) . Individual 
protons and neutrons have ±½ spin. Two protons (or two neutrons) in 
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one nucleus cancel out the spins between them  (Beall et al. ,  1984; Buxton,  
2002). Elements with unpaired spins have an overall non -zero nuclear 
spin (I) and, thus, a magnetic dipole moment (MDM) associated with it  
(Jackson and Fox,  1999; Pykett et al. ,  1982)  as represented by equation 
3-1.  
      
3-1 
where P = (h / 2п).[I(I+1)] ½  (h = Planck‘s constant = 6.63 x 10 -34 
kg .m .s - 1) is the angular moment associated with the nucleus and γ is 
called the gyromagnetic (or magnetogyric) ratio  (Jackson and Fox, 1999; 
James Jr et  al. ,  1982; Pykett  et  al. ,  1982) .  
Nuclei with non-zero magnetic moment associated with them are 
exploited by MRI (Buxton, 2002; Rohlf and Collings,  1994) . Table 1 shows 
the nuclei that  are used commonly during MRI.  The most commonly used 
amongst them is  the hydrogen nucleus ( 1H), also called the proton, 
because of its abundance in the human body (Beall et al. ,  1984; 





Neutrons Net Spin γ (MHz/T) 
Biological 
Abundance (%) 
1H 1 0 1/2 42.58 
0.63 
2H 1 1 1 6.54 
31P 1 0 1/2 17.25 0.0024 
23Na 1 2 3/2 11.27 0.00041 
14N 1 1 1 3.08 0.015 
13C 0 1 1/2 10.71 0.094 
19F 1 0 1/2 40.08 - 
Table 1: Nuclei commonly used for MRI 
Under normal conditions , magnetic moments from multiple protons are 
randomly distributed. When placed in strong external static magnetic  
field (B0) along the Z direction, these individual MDMs (µ , plural µs) 
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rearrange themselves either in a low energy state where their magnetic 
moments are parallel to the direction of the B0 or in a high energy state 
where their µs are in exact opposite direction a s per Boltzmann‘s  
distribution (Figure 7).  The two energy states are represented by equation 
3-2.  
m i  is  ±½ for a proton ( 1H isotope of hydrogen, found in abundance in -
vivo) and h is Planck‘s constant (6 .626 x 10 - 3 4  kg.m/s).  
Absence of external magnetic field B0 Presence of external magnetic field B0 
B0 
m = -½ 
m = +½ 
ΔE γ hB0/2п 0 
Figure 7: Random individual magnetic dipole moments, when exposed to strong external magnetic field B0, realign 
themselves in either the high energy state, in the direction opposite to B0, or in the low energy state in the direction 
parallel to B0. 
Individual magnetic dipole moments µ precessing 
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The effective net magnetization  (M) is the sum of all the µs. When the 
system is at Boltzmann‘s equilibrium, there are more µs in the lower 
energy state (i.e.  in the same direction as Bo) than in the higher energy 
state (  i .e.  in the direction of  –B0). Thus, the effective net magnetization 
M is in the direction of B0. The projections of the µs in the X-Y plane 
cancel themselves out  (Figure 6).  The net magnetization at  Boltzmann‘s 
equilibrium is usually denoted by M 0 .  M0  depends purely on the B0 
strength and the density of protons in the sample called the proton 
density (ρ)  (Beall et al. ,  1984; James Jr et al. ,  1982; Liu et al . ,  1989) . 
While in these energy states, these protons continue to precess at  
frequency ω,  Larmor frequency  (Bargmann et al. ,  1959) , given by the 
Effective total magnetization (Mz) at Boltzmann’s 
equilibrium 
Figure 8: Upon application of RF pulse B1, the net magnetization is rotated though a certain angle θ depending upon 






Effective total magnetization (M) and its longitudinal 
component Mz and transverse component MX-Y upon 











Larmor equation 3-3 
         




If enough energy is  supplied, these µs  can move to the higher en ergy 
states, effectively changing the direction of M (James Jr et al. ,  1982) .  
(Figure 8)  
This required energy is supplied in the form of  a radio frequency (RF) 
pulse at the frequency ω/2п  (Pykett et al . ,  1982) , at right angle to B0  and 
is denoted by B1. Since B1 is at the same frequency as the µs, the protons 
at resonance start to absorb energy and start moving to the higher energy 
state.  As more and more µs move to the higher energy state,  the net  
magnetization is rotated to wards the X-Y plane. The angle through which 
the net magnetization is rotated (θ ,  equation 3-4) is called the fl ip angle . 
θ depends upon the duration (t) and strength (B1) of the RF pulse, hence 
in turn,  on the total energy supplied  (James Jr et al. ,  1982; Pykett et al. ,  
1982). 
        
3-4 
If B1 is applied such that θ = 90°, then the entire M 0  is  rotated to the X-
Y plane. i .  e.  M X - Y  = M0  and M z  = 0; and if  θ = 180° then M X - Y  = 0 and M z  = 
M0 .  
Longitudinal and Transverse relaxations 
After the RF pulse B1 is removed, the net  magnetization starts to return 
to the Boltzmann equilibrium (James Jr et al. ,  1982; Pykett et al. ,  1982) .  
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This recovery happens due to two mechanisms. The first mechanism is 
called the transverse relaxation. During transverse relaxation, the X-Y 
component of the net magnetization, M X - Y ,  disperses in what is called the 
transverse relaxation time or spin-spin relaxation time, T2 (James Jr et  
al. ,  1982; Pykett  et  al. ,  1982) .  
While under influence of B1, all the µs are in coherence and all the 
protons are spinning at the same frequency as B1, which is the Larmor 
frequency. The µs cannot stay aligned with each other after the B1 is  
removed. As they start to disperse and relax, e very proton experiences 
not just the B0 ,  but also the magnetic  field produced by the µs of  the 
neighboring protons. This makes the net magnetic field experienced by 
each individual proton, slightly different from the one experienced by the 
other protons, causing them to start  spinning at s lightly different 
frequencies from each other. The result is an even larger difference 
between the external magnetization experienced by individual protons , 
Figure 9: Transverse relaxation. After the B1 pulse is removed, the transverse component of the net 
magnetization disperses with T2 (or T2*) decay. 






leading to loss of coherence between them. Hence, transverse relaxation 
is also called the spin-spin relaxation (Hinshaw and Lent, 1983; James Jr 
et al. ,  1982; Pykett et al. ,  1982) . At any point of time t,  the transverse 
magnetization MX - Y  is given by equation 3-5. 
       sin    
  /   
3-5 
Where, θ  is  the fl ip angle. In practice, MX - Y  decays at a rate faster than 
T2 because of additional factors such as inhomogeneities in the magnetic  
field, susceptibility and diffusion.  The resultant faster transverse decay 
time is called T2* (Buxton, 2002; Haacke et al. ,  1999; Pykett et al. ,  1982) . 
MX - Y  at any point of  time during  T2* decay, can be computed simply by 
replacing T2 from the equations 3-5 with T2*value.  As the size of the 
molecule that the protons are bound within increases, it  increases the 








Figure 10: Longitudinal relaxation. After B1 is removed, Mz slowly relaxes to its Boltzmann equilibrium value. 
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the T2 time decreases as the molecular size increases (Figure 11). 
In the second mechanism, the Z component of the magnetization 
recovers at  a s lower pace. The time for this  recovery is called the 
longitudinal relaxation time or spin -lattice relaxation time, T1. T1 is 
dependent on how effectively the proton can transfer the excess energy to 
the surrounding lattice , in order to return to the ground/stable state  
(Hinshaw and Lent,  1983; James Jr et  al. ,  1982; Pykett et al. ,  1982) . 
Hence,  the higher the resonance between the lattice  and the proton, the 
shorter the T1. At any point of time (t) during the longitudinal rela xation,  
the value of M z  can be calculated as  
            
 
 
    
3-6 
where n = 1-cosθ.  
As the molecular size increases , the T1 relaxation time decreases and 
attains a minimum where the aver age rotational/translational frequency 
of the molecules matches the Larmor frequency. As the molecular size 
increases further, the T1 relaxation time also increases due to the 
increasing mismatch between the average molecular 
rotational/translational frequ ency and the Larmor frequency.  
 Thus, T1, T2, T2* and ρ depend on the biological  sample and the 
magnitude of the main magnetic f ield (B o).  These are also the 
contributing factors to the contrast seen in most magnetic resonance 
images (Henderson,  1983; Liu et al. ,  1989; Pykett et al. ,  1982) . The 
acquisition time at which the signal is acquired after the initial excitation 





Figure 11: Plot of T1 and T2 relaxation times versus molecular correlation time (τc). For bulk water, T1 and T2 relaxation 
times are nearly identical (this is the so-called ‘extreme narrowing’ regime), while for larger molecules, such as lipids 
and proteins, T1 and T2 differ significantly. The dependency of T1 on the main magnetic field strength, Bo, is clearly 
demonstrated for medium-sized and large molecules. The minimum in the T1 curves is the point at which the rotational 








T1 contrast Mz 
Figure 12: A. T1 contrast due to differences in T1 values of different tissues. The signal with a lower T1 
(solid line) relaxes faster than signal with a higher T1 (dotted Line); B. T2 contrast due to different T2 
vales of different tissues. Signal with lower T2 (dotted line) versus signal with longer T2 (solid line) have 
different MX-Y values at the same time; hence result in different MRI intensities. In both cases, the 






















Figure 13: As the M spirals back to its Boltzmann equilibrium position in Z direction, its X-Y component (MX-Y) induces an 
oscillating current into a receiver coil called the free induction decay (FID) before the individual proton MDMs (µX-Ys) 
dephase off. The rate of decay of FID is e
-t/T2*
. 





M spirals back to its  Boltzmann equilibrium position in Z direction  after 
B1 is removed. During this time,  its  X-Y component, MX - Y ,  is also 
changing.  Before all the µX - Ys (X-Y components of  µs ) are completely  
dispersed off  because o f T2* decay, the oscillating magnetization induces 
an oscillating current into a receiver coil (Henderson, 1983; Hinshaw and 
Lent, 1983) according to the Faraday‘s law of induction. This oscillating  
signal is called the f ree induction decay (FID)(Kumar et  al. ,  1975) . 
(Figure 13) ‗Free‘ ,  because it  is not under the influence of B1 anymore;  
and decay, because it  decays to zero. The receiver coil is designed to 
measure the signal present in the X -Y plane. Hence,  to collect either the 
transverse or the longitudinal component of M, it  has to be moved to the 
X-Y plane. When X-Y components of the µs, µX - Ys, are dephased, they 
cancel each other out ,  hence, making the signal intensity zero.  In order to 
induce sufficient signal into the receiver coil,  it  is important that all µ X - Ys 
are in phase. The active rephasing and dephasing of the X -Y components 
is achieved by a sequence of RF pulses and/or a sequence of gradients 
called the pulse sequence.  In order to understand how these pulse 
sequences work,  it  is  important to understand an echo.  
Echo 
After removal of B1, each of the µs experiences a slightly di fferent 
external magnetic field due to the surrounding µs. This makes the speed,  
at with these µ X - Ys are dispersing off,  different from each other. Some of  
them are fast while some are slow  (Figure 15).  They can be refocused by 
either f lipping them through 180° , so that instead of going away from 
each other they start to move towards each other,  or by exerting  
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additional external magnetic field , so that they are forced back together.  
When they finally come back in phase ,  the signal  received is called an 
echo (Haacke et  al. ,  1999; Hahn, 1950) .  
 
Spin Echo RF pulse sequence 
In a spin-echo pulse sequence, the rephasing of µ X - Ys is achieved using a 
180° RF pulse (James Jr et al. ,  1982; Liu et al. ,  1989) . Initially we excite 
M by applying B1 pulse (the Figure 15 has θ = 90°). Right after the B1 
pulse is removed, the µX - Ys start to dephase. After dephasing for some 
time, the fastest µ X - Y  is leading and the slowest one is trai l ing. At that 
time, an additional 180° B1 pulse is applied, such that now, the µX - Ys are 
flipped. The fastest  µ X - Y  is now trailing, and the slowest one is in the lead. 
That way,  the fast µ X - Ys catch up to the slow ones in the same time that  
was given for dephasing in the first place. This gives rise to  an echo 
(Pykett et al. ,  1982) . This time to echo, from the application of the first 
90° RF pulse, is denoted by TE, and hence, the 180° pulse is applied 
Figure 14: Echoes achieved by active rephasing of individual proton 




exactly at TE/2 (Figure 16).  The signal acquired using a spin echo 
sequence is T2 weighted and is unaffected by field inhomogeneity , and 
hence,  T2* (Buxton, 2002; Haacke et al . ,  1999) . 
Gradient  Echo RF pulse sequence 
During a gradient echo pulse sequence, we do not apply the 180° 
refocusing pulse,  as  in the spin echo sequence  (Buxton, 2002). Instead,  
an additional gradient is applied called the readout gradient  in the 
frequency encoding direction. (Figure 17) Since this sequence forces the 
spins together and does not require an additional 180° pulse, it  is much 
faster than the spin-echo sequences.  Gradient echo signal intensity is 
weighted by T2*, which makes it  a preferable for blood oxygenation level  
dependent functional MRI scanning.  The signal acquired using a gradient 
echo pulse sequence is affected by susceptibility artifacts  which occur at 
the interfaces of two materials of different magnetic susceptibilit ies like 
air and tissue interface near the sinus cavity  (Buxton, 2002; Haacke et 





Figure 15: Formation of a spin in Spin Echo. Initially M0 is aligned with B0 (A). A 90° RF pulse knocks M0 to the X-Y 
plane (B). After TE/2 time, the X-Y components of individual magnetic dipole moments (µX-Y) are dispersed with the 
fastest component leading and hence the farthest from the initial MX-Y position (C). Another 180° RF pulse flips the 
µX-Ys such that the fastest component is now trailing (D) and after another TE/2 time, all the µX-Ys come back in focus 









Figure 16: Spin Echo pulse sequence. GS, Slice selection gradient; GP, Phase encoding gradient; GF, 
Frequency encoding gradient; TR, Repetition time; TE, Time to echo. 
Figure 17: Gradient Echo pulse sequence. GS, Slice selection gradient; GP, Phase encoding gradient; GF, 




The collected signal is spatially encoded by additional magnetic  
gradients across X, Y and Z direction which change the B0 field from one 
point to the other ,  depending on the slope of the applied gradient  
(Haacke et al. ,  1999; 
Kumar et al. ,  1975) . The Z 
gradient is applied along 
the B0 field and is applied 
during the application of  
the B1 RF pulse.  This  
changes the Larmor 
frequency of the sample 
across the Z direction.  
This ensures that only one slice of the sample is  in resonance with B1, 
and hence, it  is the only one that is activated. Therefore, the Z gradient is  
also called the slice selection gradient. The smallest resolution in an MRI 
slice is a 3 dimensional volume called a voxel.  The size of  a voxel is  
determined by the slice thickness and in -slice resolution determined by 
the frequency and phase encoding gradients which will be discussed 
ahead.  The X and the Y gradients ,  applied after the B1 pulse, are 
respectively called the frequency and phase encoding gradients.  These 
gradients make protons each point within the selected slice experience a  
different magnetic field , making the protons to  relax at different rates.  
This results  in difference in the frequency and phase of the signal from 
each point within the selected slice. These parameters are u sed later to 
decide the position of the received signal.  
B0 
X, Y, or Z direction B0 - ΔBj 





Figure 18: When a gradient of slope m is applied in one direction, 





During MRI, slices are selected along the Z-direction, and hence, the 
slice selection grading is the Z-gradient.  Z-gradient causes the Larmor 
frequencies along the Z axis  to change  e.g. ω1, ω2 as shown in Figure 19.   
If  we apply a B1 pulse with frequencies ω2±ωi, where ωi is a small  
value, it  only excited spins in a thin slice around ω2 and the thickness of  
the slice is decided by the bandwidth ±ωi and the sl ope of s lice selection 
gradient applied (Haacke et al. ,  1999; James Jr et al. ,  1982; Pykett et al. ,  
1982).  
Usually,  the applied Z gradient is not completely homogenous and can 
induce additional inhomogeneity to the spins causing them to dephase 
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Figure 19: Slice selection. The gradient changes the Larmor frequencies along the Z axis. By selecting 






of the B1 pulse,  a reverse Z-gradient is 
applied of the half  the power (amplitude 
x time / 2) of the f irst  Z -gradient.  The 
timing diagram for the Z-gradient and B1 
pulse is shown in Figure 20.  
Phase encoding 
After the slice selection RF pulse and 
the refocusing part of the Z-gradient are removed, all the spins in that  
slice are excited and are dephasing under the influence of B0. In order to 
delineate between point to point within the slice , a phase encoding 
gradient is applied along the Y axis.  This causes the spins in different 
lines along the Y axis to dephase at different rates, while the Y-gradient is  
on. As soon as the Y gradient is off,  the spins go back to their original 
frequency, but maintain the phase that  was imparted upon them.  In a 
single slice, only one of the phase -encoded lines is collected at one t ime. 
Hence, during the collection of a 64 x 64 voxel slice, the phase encoding 
gradient steps through 64 steps  (Buxton, 2002; Haacke et al. ,  1999; 
Kumar et al. ,  1975) .  
Frequency encoding 
Frequency encoding is usually the last step of spatial  encoding. It  is  
applied in a direction perpendicular to the phase encoding gradient , and 
it  also changes the Larmor frequency of the spins. The difference is that,  
unlike the phase encoding gradient, the frequency encoding gradient is  
applied at the time the signal echo is being collected. This ensures that 
the signal acquired from different points in space has a different 







frequency associated with it .  During each step of phase encoding 
gradient, one l ine of frequency encoded gradient is collected. Hence, for a 
64 x 64 voxel s lice, signal acquired during one phase encoding step, is a 
collection of 64 discrete frequencies  (Buxton, 2002; Haacke et al. ,  1999; 
Kumar et al. ,  1975) .  
To summarize, one slice is acquired at a time, and each point in the 
selected slice has a unique frequency and unique phase associated with it  
as depicted in Figure 21. A single line of  frequency encoded signal in the 
phase encoding direction is acquired during one TR period .  Hence, ‗n‘  TR 
periods are needed to acquire a slice with n x n voxels.  
K-space 
Frequency and phase encoded signal,  received in the receiver coil ,  needs 
to be deciphered in order to re-establish the physical location of the 
















Figure 21:  Signal from each point in the selected slice has a unique frequency and phase associated with it. 
























is called the k-space of the image or raw data. The image reconstruction 
is achieved by applying the techniques of Fourier  transform to the raw 
data (Pykett et al. ,  1982) .  
Fourier transform and MRI 
Fourier transform (FT), is a mathematical technique that transforms a 
time-domain signal into its equivalent  frequency-domain representation.  
A sine wave of frequency f and amplitude A in time domain, is  
represented by a single point on the frequency domain plot at ( f,A) with 
frequency on the x axis and amplitude on the y axis  as shown in Figure 
22.  Therefore, a signal that  is a combinati on of various frequencies of 
different amplitudes, when Fourier transformed, can be represented by 
multiple points in the frequency domain. This enables the separation of 
the various frequencies  (Haacke et al. ,  1999; Oppenheim et al. ,  1999) .  
Conversely, inverse Fourier transform (IFT) can trans form a frequency 
domain signal into its time domain representation.   
Joseph Fourier (1768-1830) was the first one to use FT technique to 




look at heat dissipation.  Richard Ernst proposed the use of FT in MRI in 
1975 (Ernst,  2007; Kumar et al. ,  1975) . In MRI, FT is applicable in 
excitation, as well as,  in signal acquisition. The single slice excitation is  
achieved by application of RF B1  pulse of a small bandwidth.  In order to 
achieve the rectangular frequency domain excitation pulse ,  as shown in 
Figure 19, its  Fourier transform pair in t ime domain is  applied. Figure 23 
depicts the Fourier  transform pair of a rectangular function called a 
continuous SINC function given by sin(x)/x. In practice,  it  is  not possible 
to apply an infinitely continuous SINC wave and is approximated by 
applying a series of short rectangular pu lses (Haacke et al . ,  1999) .  
The MRI signal acquired through the receiver coil ,  is a combination of  
multiple frequencies and different phases with their amplitudes 
representing the signal intensities.  It  is important to note that,  the 
Fourier transform representation of a signal is a combination of real and 
imaginary parts,  which together represent the amplitude, as well as,  the 
phase of the signal.  Therefore, t he reconstruction of the image from the 
raw data in the frequency, phase and intensity format is achieved by 
applying two dimensional inverse Fourier transform to it  (Kumar et al. ,  
1975). 
Figure 23: Fourier transform pair. SINC wave and a rectangular function are Fourier transform pairs of each other 




Functional MRI (fMRI) is a leading technique for mapping the activity 
in different brain regions under various conditions. In 1990,  Seji Ogawa 
demonstrated that ,  the presence of deoxyhemoglobin changes the T2* 
relaxation time of blood, hence, making it  appear darker on echo -planner 
images (Ogawa et al. ,  1990b; Ogawa et al . ,  199 0a).  Ogawa suggested that  
blood deoxygenation can indeed be used as  an endogenous contrast agent.  
John W. Belliveau  and colleagues performed the f irst hum an functional 
MRI experiment using visual stimulus and demonstrated that  the 
stimulation results in blood volume changes in the visual cortex 
(Belliveau et al . ,  1991) .  Almost immediately following Belliveau,  
additional work was done in humans demonstrating blood oxygenation 
level dependent changes in various cortical area s in a task dependent 
manner (Bandettini  et al. ,  1992; Kwong et al. ,  1992; Menon et  al. ,  1992) .  
Hemodynamic response, deoxyhemoglobin and MRI signal 
Figure 24: Signal intensity changes in the visual cortex following visual stimulation shown by Kwong and colleagues. 











There is an 
increase in 
deoxyhemoglobin 
for a brief period 
of time 
Hemodynamic response 
overcompensates for the 
demand of oxygen and 
glucose. 
Increase in local blood 
volume and drop in 
deoxyhemoglobin below 
normal conditions 
Figure 25: Hemodynamic response to neural activation. 
―Local cerebral glucose 
metabolic rate (CMRglu) and 
cerebral blood flow (CBF) are 
greatly increased by focal 
increases in neural activity… 
Challenging the conventional 
formulation, we reported that a 
focal,  physiological increase in 
neutral activity induced by 
peripheral tacti le stimulation 
increased cerebral metabolic  
rate for O2 (CMRo2) minimally 
(5%), despite a large increase 
(29%) in local CBF.‖  (Fox et al. ,  
1988)  
Under non-stimulated 
conditions, a brain region 
receives steady supply of blood 
flow and has basal 
levels  of oxygenated 
and deoxygenated 
blood present in the 
capillaries around it  
(Buxton, 2002). As a 


























Figure 26: Glucose metabolism in tissue. Dashed line  
represents the glycolysis. 
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active during a neural response, there is an increase in the energy 
requirement and corresponding glucose metabolism (CMRglu) . Activation 
also leads to an increase in the blood flow (CBF) to that  region and 
resultant increase in the local blood volume (CBV)  (Buxton, 2002). The 
initial  belief  was that ,  the increases in CBF and CBV are to compensate 
for increased energy demand and CMRglu. However, a 17% increase 
reported in the CMRglu does not explain the almost 30% rise in CBF 
measured using positron emission tomography (PET) (Fox et al. ,  1988) . 
Hence, the extent of CBF increase  is  not well understood (Buxton, 2002). 
In addition to  a r ise in CMRglu, increase in oxygen consumption 
(CMRo2) is also reported during brain activation. A significant 
correlation has been reported between the variations in CMRo2 and CBF 
along with changes in stimulation frequencies  (Hoge et al . ,  1999a; Hoge 
et al. ,  1999b). However, the increase in CMRo2 is reported to be only 5% 
(Fox et al. ,  1988). This has resulted in a conclusion that ,  the increase in 
CMRglu is mostly due to glycolysis ,  unlike the slower oxidative 
metabolism of glucose. This has further been supported by an increase in 
lactate in the active brain regions as measured in mag netic resonance 
spectroscopy (Prichard et al. ,  1991; Sappey -Marinier et al. ,  1992; Singh, 
1992). However,  glycolysis is not as efficient in energy generation as the 
oxidative metabolism. In fact it  can produce only as much as 1/16 of ATP 
(energy units in body) as  the oxidative metabolism. This has led to the 
conclusion that the increase in energy consumption in the  active state is 
of much smaller units than the increase in CMRglu and CBF.   
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Hence, the reason for overcompensation of CBF is still  unclear. One 
speculation is  that the overcompensation has  evolved as a preemptive 
preventive measure against oxidative stres s, causing ischemic damage to 
the brain cells  (Squire, 2003).  
Blood oxygenation level dependent fMRI 
Blood oxygenation level dependent (BOLD) fMRI is based the fact that 
there is  a change in the blood oxygen level in a brain region under 
stimulated conditions as compared to the baseline un -stimulated 
condition. Deoxyhemoglobin (dOHb) is param agnetic in nature due to the 
unpaired electron within the heme- group (Reimer and Parizel,  2006)  and 
gives rise to inhomogeneity in the surrounding magnetization (Ogawa et  
al. ,  1990b; Ogawa et al. ,  1990a) . This inhomogeneity results in T2* 
shortening. Hence,  more the dOHb in a region, the faster are the spins in 
that region dephased. This leads to reduction of the MRI signal induced 
into the receiver coil .   
Under normal conditions, the basal levels of oxyhemoglobin (OHb) and 
dOHb result in a baseline of  MRI signal.  At the onset of the neural 
activity in a brain regon, there is a momentary increase in the dOHb in 
that region. This  can be observed as an initial ‗dip‘ in the fMRI signal.  As 
the hemodynamic response increases the blood volume in that region, the 
OHb levels start to rise. The overcompensation of CBF leads to a drop in 
the dOHb/OHb ratio , even below the values at the baseline.  OHb is  
diamagnetic,  and hence, does not cause any inhomogeneities.  This leads 
to a rise in the overall T2* allowing the spins to disperse at a slower rate ;  
thus, resulting in  an increase in the MRI signal intensity.  
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Most of the BOLD fMRI studies use block design , where the subject is  
imaged though periods of ‗control‘  blocks interleaved with ‗ task‘ blocks. 
Multiple volumes of the fMRI images are collected through each of  the 
blocks. Figure 27 represents a single block design, where the baseline is  
the control block and the stimulation is  the task block . BOLD change is 
calculated as the change in signal intensity  during the stimulation period ,  
as a percentage of the baseline signal intensity .   
Resting state MRI 
Our brain is a highly wired network of connections. The level of 
functional connectivity of the brain is even higher than the mere 
BOLD signal 
Figure 27: BOLD response. Right after the stimulus the amount of deoxyhemoglobin increases momentarily before 
it is overcompensated for by the hemodynamic response. 
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anatomical connectivity. BOLD activation based functional MRI focuses 
solely on changes in blood oxygenation of isolated brain regions under 
consideration, with respect to the applied stimuli.  As described by 
Hebbian theory, ‗Neuron‘s that fire together wire together‘,  brain regions 
that have anatomical and/or functional connectivity should have 
significant temporal correlation between their activities.   
Biswal‘s group was the first one to demonstrate existence of resting 
state connectivity. They performed two fMRI scans in each subject.  In the 
first  scan, they asked the subjects to rest without any cognitive, language,  
or motor tasks as much as possible ,  and the second scan was performed 
with a finger tapping task (Biswal et al. ,  1995) . They found that the pixels  
activated during the task-related fMRI, also had significant correlation 
between them during the resting state (RS) scans. Shulman and 
colleagues observed decreased activity in various brain regions during 
cognitive tasks in their PET study (Shulman et al. ,  1997) . The observed 
decreases were independent of  the task. Raichle et.  al.  demonstrated 
steady oxygen extraction fraction in the brain during resting PET studies  
(Raichle et al. ,  2001) . They proposed that brain has a default mode 
network, which is constantly active .  This network is performing tasks,  
such as,  information gathering with respect to possible predatory attack,  
without conscious attention to it  (Gusnard et al. ,  2001; Raichle et al. ,  
2001).  Shulman group observed activity during stimulation in certain 
brain regions, which has been proposed as the turning off of the default  
mode network, while one needs to pay conscious attention to a  particular  
task (Raichle et al. ,  2001; Shulman et al. ,  1997) . Shmuel and Leopold 
recently demonstrated that BOLD signals have significant correlation 
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with local field potentials  of neural activity in monkeys (Shmuel and 
Leopold, 2008). Hence, any correlation between the BOLD signals from 
two brain regions should indicate correlation between neural activities at  
the two regions. By this,  temporal correlations in low frequency 
fluctuations (<0.1Hz) in BOLD signals recorded at different brain regions 
are considered a measure of functional connectivity between thos e 
regions (Biswal et al. ,  1997) . The cardiac and respiratory signals in 
humans are in the rage of 0.6-1.1Hz and 0.1-0.5Hz, respectively (Cordes 
et al. ,  2001). In rats,  the cardiac frequency is of the order of  4 -5Hz and 
the respiratory frequency is  of the range of ~1Hz (Majeed et al. ,  2009; 
Williams et  al. ,  2006) .  
Temporal correlations between cortical  BOLD signals  have more than 
90% contribution from signal frequencies below 0.1Hz, with less than 10% 
contribution from the respiratory and cardiac signals in humans as shown 
Figure 28: Contribution of various frequency ranges in the correlation coefficients for various seed regions (Cordes 
et al., 2001). Frequencies below 0.1Hz have higher contribution towards correlation coefficients for cortical areas. 
Reproduced with permission. 
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by Cordes group in Figure 28 (Cordes et  al. ,  2001); whereas,  frequencies 
higher than 0.1Hz contribute towards the arterial and cerebral spinal 
fluid signal correlation with the rest of  the brain .  Williams groups has 
reported similar observations in rats,  where the cortical correlations have 
higher specificity at frequencies below 0.1Hz (Williams et  al. ,  2006) . 
Technical instabilities,  such as magnet drift  have been shown to be 
corrected by low pass filtering the data (Williams et al. ,  2006) . Fox and 
colleagues has added to the understanding of the resting state network by 
showing that resting state connectivity can indeed be an indicative of  
performance (Fox et al. ,  2007) .  
As demonstrated in Figure 29, RS connectivity of any brain region can 
be computed by calculating the correlation coefficient of the average 
temporal fluctuations in that brain region (blue) with the temporal 
fluctuations of every voxel (red) in the brain .   
RS connectivity has been observed in humans and animals , in conscious,  
as well as,  in un-conscious state (Biswal and Kannurpatti,  2009; Greicius 
Figure 29: Temporal correlation between time series from two brain regions is an indicator of connectivity between 
the two regions. An average of low frequency BOLD signal fluctuations from all the voxels that lie within a chosen 
seed (blue) is generated.  The correlation coefficient of this averaged timecourse, with that from every voxel within 




et al. ,  2008; Pawela et al. ,  2008; Zhang et al. ,  2010) . It  is a very sensitive 
to brain network alterations, and has been shown to change under 
different affected states such as Alzheimer‘s Disease (AD) (Lustig et al. ,  
2003; Rombouts and Scheltens,  2005), Depression (Anand et al. ,  2005) , 
ADHD(Tian et al . ,  2006) , Multiple Sclerosis (MS) (Lowe et al. ,  2008;  
Lowe et al. ,  2002)  and even during normal aging (Andrews-Hanna et al. ,  
2007).  
Summary 
Magnetic resonance imaging is a non -invasive imaging technique 
employing the property of magnetic di pole moment associated with 
unpaired nuclear spins existing in certain elements.  These magnetic  
dipole moments, when subjected to a high external magnetic field, realign 
themselves in the direction of that field.  If  pushed out of that alignment 
by the presence of a second magnetic field, they follow a specific  pattern 
while regaining their previous orientation after the secondary field is  
removed. This  process of re -orientation gives rise to the MRI signal.  
Functional MRI exploits the paramagnetic property of deoxyhemoglobin 
and the over-supply of oxygenated blood to an activated brain region as  
determined by the hemodynamic response, to indirectly map the neural 
activation in that region. This makes it  a very useful technique in the 




Chapter 4. Model development 
Animal Models of Parkinson’s disease 
Animal models play an important role in medical research . They provide 
a researcher an opportunity to control various factors such as age,  
environment, diet and disease stages.  
Currently,  a variety of animal models are available for the study of PD, 
ranging from genetic  based to toxin induced  models.   The genetic  models  
in mice or flies have been rather informative regarding the etiology and 
pathogenesis of PD. However, generally these models either  fail to show 
the distinctive neuropathology, such as loss of dopamine in the striatum , 
or have a complex breeding scheme, making them expensive to use  (Bove 
et al. ,  2005; Terzioglu and Galter,  2008) . In contrast  to genetic 
determinants, the vast majority of PD cases are thought to be caused by 
environmental factors  (Caudle and Zhang, 2009; Tanner, 2010) .  
Therefore,  the primary focus of this study has been  on environmental 
approaches to PD symptoms and the neuropathology, as manifested in an 
animal model exposed to neuro toxins.   
Toxins currently in use to develop Parkinsonian animal models include 
6-hydroxy dopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-
Tetrahydropyridine ( MPTP), paraquat and rotenone(Terzioglu and Galter,  
2008). Among these,  MPTP is ineffective in causing neurotoxicity to 
dopaminergic cells in the rat for reasons which are not understood.  
Paraquat and rotenone‘s  effect s on the nigrostriatal pathway are 
inconsistent and unpredictable(Bove et al. ,  2005) . Results by Terizioglu 
et.  al.  (Figure 30) summarize advantages and disadvantages  of various 
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models (Terzioglu and Galter,  2008) . Based on this knowledge, 6-OHDA 
was used to develop the model for our studies.  
6-Hydroxy dopamine 
The neurotoxin 6-OHDA is a dopamine analog, sharing some structural 
similarities with dopamine. It  is easily taken up by dopamine transporters  
and known to cause oxidative stress, mitochondrial damage and neuro -
inflamation (Na et al. ,  2010; Schober, 2004) . Ungerstedt was the first to  
use 6-OHDA to produce dopaminergic lesions of the nigrostriatal system 
in the rat  (Ungerstedt, 1968) . This neurotoxin is not able to cross the 
blood brain barrier and if  delivered systemically,  it  causes damage to the 
peripheral nervous system. Hence,  the preferred route of administration 
for this toxin is intracranial delivery into specific brain region s. These 
injections produce localized dopamine depletion, making it  possible to 
control the site and extent of  lesion.  In turn, this  makes it  possible to  
monitor and study the effects of  dopamine lesions in different parts of the 
brain.  
The exact pathways of 6-OHDA toxicity are not completely understood. 
An in-vitro study by Hanrott group showed that 6-OHDA is auto-oxidized 
to hydrogen peroxide within 5 minutes  in extracellular space, which 
eventually causes oxidative stress leading to cell death  (Hanrott et al. ,  
2006).  PC12 (rat pheochromocytoma cell line)  cells exposed to 6-OHDA 
in the same study started to exhibit mitochondrial damage starting at 6 
hours post treatment and loss of membrane integrity indicating cell  death 
starting at  10 hours post treatment.  Na et.  al. ‘s  study in rats with striatal  
lesions of 6-OHDA, points towards robust inflammatory response in both 
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the striatum and SN (Na et al. ,  2010). Another review paper by Andreas 
Schrober points out oxidative stress, mitochondrial damage and 
inflammatory response as results of various 6 -OHDA lesion studies 
(Schober, 2004). These effects are very similar to the PD etiology in that  
similar observation have been made in postmortem studies in PD patients  
(Gaig and Tolosa, 2009) .  
Over the years, many different sites of 6-OHDA infusions have been 
studied, including substantia nigra (SN), medial forebrain bundle and the 
striatum. The most extensively studied SN  and MFB lesions, consistently 
produce motor deficits and are thus util ized to model the motor deficits 
in PD (Deumens et  al . ,  2002; Sakai  and Gash, 1994) . Usually,  these 
lesions are severe and result in significant gait changes, such as shorter 
stride length, reduced limb swings while walking, reduction in paw 
contact and paw pressure, aphagia (problem in swallowing) , akinesia,  
amphetamine induced rotations in the unilateral models and massive loss 
of dopamine cells in SN (Chuang et  al. ,  2010; Deumens et al. ,  2002; Sakai  
and Gash, 1994). These models  provide a practical  way of testing 
treatment for motor deficits .  However,  severe motor deficits make it  
difficult  to test  any non-motor symptoms that are commo nly observed in 
the pre-motor and early stages of PD. 
When injected into the striatum, 6-OHDA causes local reduction of  
dopamine content in the striatum and retrograde degeneration of 
dopamine cells in  the SN (Blandini et al. ,  2007; Fleming et al. ,  2005; 
Yuan et al. ,  2005). These lesions are progressive in nature and result in  
lower levels of  dopamine cell  loss over a period of many weeks after the 
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insult  (Sauer and Oertel,  1994) . This allows the testing of potentially 
neuroprotective treatments in a time dependent manner, which is much 
more relevant to clinical treatment regimens  (Lindholm et  al. ,  2007) . 
Double bilateral lesions of the striatum with  6-OHDA have shown to 
produce long lasting dopamine loss without compensatory effects weeks 
after the infusion (Ben et al. ,  1999) . As discussed in Chapter 2, striatal 
dopamine depletion has been observed in early -stage PD patients and is  
projected to date back many years b efore the onset of  the clinical 
symptoms. As discussed in Chapter 2, striatal dopamine has reduced by 
almost 80% and the there is almost 50% loss of substantia nigra cells by 
the time onset  of motor symptoms in PD. Hence,  the striatal 6-OHDA 





Scoring of dopamine neuron: slight loss (< 30%);  loss (30–70%); massive loss (> 70%). The construct validity of a model 
refers to the degree to which the rodent model reproduces known PD etiology (low = no findings in PD patients indicate a role 
in PD etiology for the toxin or genetic modification that the model is based on; poor = some findings point to a role in PD 
etiology; good = findings in PD patients indicate a causative role for genetic modifications reproduced in the model);  KO, 
knock out. 
Figure 30: Summary and advantages and disadvantages of selected rodent models of PD. (Terzioglu and Galter, 2008) 





Adult male Long Evans rats (300-350g, N= 48) were obtained from 
Harlan Sprague–Dawley Laboratories (Indianapolis,  IN). The a nimals 
were group-housed (2 per cage) in Plexiglas cages and maintained in 
ambient temperature (22–24°C) on a 12/12 h light/dark cycle. Food and 
water was provided ad libitum. All procedures were approved and 
monitored by the University of Massachusetts Me dical School 
Institutional Animal Care and Use Committee . Animals were randomly 
assigned to various studies as stated in Table 2. The animals from all the 
groups were age matched.  
Study Group Number of rats per 
group 
Spontaneous locomotion Control 5 




Elevated beam test Control 5 
 3WKPD 5 
 
Gait analysis Control 4 
 2WK (2weeks post 6-OHDA lesion) 4 
 3WK (3weeks post 6-OHDA lesion) 4 
 4WK(4weeks post 6-OHDA lesion) 4 
 
Immunohistochemistry Sham (Sham lesioned rats) 6 
 3WKPD 6 
Table 2: Rat assignment per motor and Immunohistochemistry studies. 
Surgery 
Rats from the 6-OHDA lesion group and sham lesion group were 
anesthetized with 3-5% Isoflurane and set up in a stereotactic system 
(myNeuroLabs, Leica Microsystems,  Richmand, IL). They were 
maintained at 1.5-2.5% Isoflurane during the surgery. The 6-OHDA lesion 
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rats received a total  of 12 g of 6-OHDA in the CPu (caudate putamen; 
0.7mm rostral to bregma, ±3mm lateral to 
midline, 5mm ventral to skull surface).  The 
infusion was achieved in two separate steps of 
10 μg and 2 μg in 1 μl of vehicle (0.1% 
Ascorbic acid in 0.9%NaCl) two days apart ,  
using PE50 tubing attached to Hamilton 
micro-syringes. The sham lesioned group went 
through the same procedure as the 6-OHDA lesion group with the 
exception of  receiving  6-OHDA. 
Spontaneous locomotion test 
At the three week time point ,  
control and 3WKPD rats  were 
allowed to freely move in a black 
Plexiglas arena (90cm x 90 cm) for 
five minutes. Their  behavior was 
recorded using an overhead 
camera.  
Elevated beam test 
The test apparatus consisted of a 
1.5 inch wide and 36 inch long 
wooden beam. One end of the beam 
had a black enclosed platform that  
the rats could rest on at the end of the test.  The entire assembly was 3.5 
feet  above the ground. Each rat was placed on the end away from the 
Figure 31: Site of 6-OHDA lesions 
Figure 32: Spontaneous locomotion test apparatus 
consisted of a 90 cm x 90 cm black Plexiglas arena. The 
rat was allowed to walk freely in it for 5 minutes. An 
overhead camera along with the Ethovision software 
(Noldus Information Technology, Leesburg, VA) recorded 
and analyzed the rat’s movement. 
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platform, and allowed to walk to the 
platform. Each rat  performed 3 trials  
and the first trial was ignored as the 
acclimation trial.  The second and  third 
trials were scored for time to cross the 
beam and number of slips during that 
time period. Time to cross the beam as 
scored starting a timer/stop watch as soon as the rat was placed on the 
far end of the beam and stopping as soon as his fore paws re ach the 
platform. A slip was defined as slip (movement off of the beam) of any of  
Location of high-speed camera 
A 
B 
Figure 34: DigiGait gait analysis system by Mouse specifics. A. Setup included a translucent treadmill. Rats 
were allowed to talk on the treadmill while a high-speed camera situated underneath recorded its 
movement. B. image taken by the high-speed camera situated underneath the treadmill. 
Figure 33: Elevated beam walk. Rat was placed at 
one end of the 1.5 inch x 36 inch wooden beam at 
3.5 feet above the ground, and allowed to walk to a 








the limbs off  of the beam during the process of placing that limb on the 
beam. Number of s lips was  recorded at the end of  each trial.  
Gait Analysis 
Controls,  and 2, 3 and 4 weeks post 6-OHDA lesion rats were tested for 
motor deficits using DigiGait Imaging system (Mouse Specifics,  Inc.,  
Quincy, MA). The system uses a transparent treadmill with a high speed 
camera situated below it.  After the gait videos were recorded, they we re 
scored for 26 different parameters concerning the stride, breaking and 
paw placement using DigiGait  analysis and imaging software  (Mouse 
Specifics,  Inc.,  Quincy, MA) .  
Immunohistochemistry 
Tyrosine hydroxylase (TH) staining was performed on rat  brain sl ices to 
determine dopamine loss in the striatum and the SN. TH is an enzyme 
responsible for the f irst step in synthesis of dopamine  from tyrosine in-
vivo, and hence serves as an indirect measure of dopamine content in 
cells (Nagatsu et al. ,  1964) . TH-staining is a commonly used technique to 
quantify dopamine.   
Sham and 3WKPD rats were anesthetized with 200mg/kg o f IP 
pentobarbital and perfused intra -cardially with 120 ml of 4% 
paraformaldehyde solution in 0.1M phosphate buffer (PFA). The rats were 
decapitated, the brains were quickly removed and post fixed for 2 hours 
in PFA, followed by another 48 hours in 30% sa line solution in 0.1M 
phosphate buffer at 4°C. The brains were frozen on dry ice and sliced into 
25um thick slices on a microtome (SM2000R, Le ica Microsystems, 
Buffalo Grove, IL). Four slices each were collected through the striatum 
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and through the SN. The slices were incubated in 1:500 Monoclonal anti -
TH mouse primary antibody (T2928, Sigma-Aldrich, St.  Louis, MO) in 1M 
PBS/0.3%Triton X-100 (TRX) overnight at 4°C. The next day, slices were 
washed in 1M PBS three times and incubated in 1:200 mouse IgG 
secondary antibody in TRX (Vectastain Elite ABC kit,  Vector Labs , 
Burlingame, CA) for 1 hour followed by H 2O2  incubation for 1 hour at room 
temperature. The slices were washed three t imes in PBS after each step.  
Finally,  the staining procedure was completed usi ng 1:50 DAB in TRX 
(D9015, Sigma-Aldrich, St.  Louis, MO) and the slices were mounted on 
slides for further analysis.  The concentrations used during the staining 
procedure were empirically determined by Akbarian lab at UMass Medical 
school after trying out various concentrations recommended by Sigma -
Aldrich in their  product sheet  for optimum staining contrast .  
Data Analysis 
Spontaneous locomotion test 
The open field behavior was analyzed using Ethovision software (Noldus 
Information Technology, Leesburg, VA)  for total distance moved in the 
five minutes.  No statistics was performed because of lack of any 
difference between the group means.  
Elevated beam walk test 
The last two trials of each rat were averaged to calculate the average 
time to cross the beam and average number of s lips per rats.  These values 
were compared between groups to test for any difference between the 
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groups.  No statistics was performed because of lack of any difference 
between the group means.  
Gait Analysis 
 DigiGait analysis and imaging s oftware by Mouse Specifics analyzed the 
gait videos for 26 different parameters . Multivariate ANOVA with 
bonferroni correction for multiple comparisons was used to compare 
groups.  Among the 27 parameters  stride frequency, stride length and 
stride duration were selected based on the significant difference observed 
in them between controls and 4 weeks post 6-OHDA rats.  These 
parameters are relevant to PD, since gait changes such as shorter and 
quicker steps are observed during Parkinsonian gait.   
TH-staining 
 Images of the slices were collected using an Olympus BX51 microscope 
attached to QICAM FAST1394 digital camera with 1.25x zoom on the 
striatum and 10x zoom on the substantia nigra.  ImageJ software 
(http://rsb.info.nih.gov/ij/) was used to calculate TH-staining intensity 
in the CPu and the TH-stained cells in the substantia nigra, as described 
by Abramoff group (Abramoff et al. ,  2004) . To measure the CPu dopamine 
content, the CPu TH-staining intensity  was measured using ImageJ. The 
Figure 35: Analysis of dopamine content in striatum and dopamine cell density in substantia nigra.  
A. For analyzing dopamine content in striatum (CPu), the average tyrosine hydroxylase staining intensity of the 
average CPu staining intensity was measured. The average corpus callosum (CC) staining intensity was subtracted 
from it as a backgroud measure.  B. To measure the substantia nigra staining intensity, the substantia nigra was 
marked as shown and the area was measured. The dopamine cell bodies in the zoomed in version are marked with 






corpus callosum staining intensity served as an internal control for  
background staining intensity ( Figure 35A). Difference between CPu 
staining intensity and corpus callosum staining intensity was recorded  for 
each brain slice. Figure 35B represents the measurement of do pamine cell 
density in substantia nigra. The substantia nigra area was marked and 
measured using ImageJ. All  the dopamine cells within the marked area 
were counted using ‗cell counter‘  plugin in ImageJ. Dopamine cells  are 
marked with arrows in zoomed in se ction of Figure 35B. Dopamine cell  
density per slice was calculated as number of cells per square µm 2  of  
substantia nigra area. Between group comparisons  were done using 
univariate ANOVA. 
Results 
There was no difference between th e total distances walked by the 
control versus the 3WKPD groups in the open field arena  (Figure 36). The 
3WKPD rats were able to cross the elevated beam in almost the same 
duration and with no additional s lips in the elevated beam walk test  
(Figure 37).  During the gait analysis test,  multivariate ANOVA with 
bonferroni correction for multiple comparisons, revealed significant main 
group effect  in stride duration (F ( 3 , 1 2 )  = 6.135, p<0.004), stride length 
(F ( 3 , 1 2 )  = 5.838, p<0.005), and stride duration (F ( 3 , 1 2 )  = 5.448, p<0.006). 
The rats at 4 week post lesion had significantly smaller stride duration 
(t ( 7 )  = 3.85, p<0.03), higher stride frequency ( t ( 7 )  = 3.15, p<0.03) and 
shorter stride length ( t ( 7 )  = 3.19, p<0.03) as compared to controls in the 
post hoc analysis.  Both , the 2 and the 3 week post lesion groups , did not 
demonstrate any significant deficits in any of the 26 parameters examined 
70 
 
during the gait analysis experiment.  However,  the 3 week post lesion r ats 
exhibited a trend in the direction of  developing deficits in stride 
frequency, stride length and stride duration (Figure 39). The smaller  
stride duration, higher stride frequency and shorter stride length are very 
analogous to the shuffling gait observed in human PD patients.  
The univariate ANOVA of the TH-staining results revealed a significant 
difference between the two groups in the CPu staining intensity 
(F ( 1 , 1 0 ) =15.9, p<0.05) and the substantia nigra cell density (F ( 1 , 1 0 )=13.454,  
p <0.05). The CPu had 27% reduction in the average TH-staining 
intensity (Figure 38A) while there was a 23% loss of the TH-stained cells  
in the substantia nigra in the 6 -OHDA lesioned rats as compared to the 
sham lesioned rats at  the three week time point  (Figure 38B).   
 Conclusion 
The dopamine loss in CPu and SN of the 6 -OHDA lesioned rats ,  at 3  
weeks post lesion, was lower than the reports of 80% striatal loss of  
dopamine and 50% dopamine cell loss in the SN in PD patients ,  at the 
time of onset of motor symptoms. The 6 -OHDA lesioned rats neither 
exhibited any motor deficits  in spontaneous locomotion, nor did they 
exhibit any changes in gait during the extensive gait analysis  at the three 
week time point.  As previously put forth in  the Braak stages of PD, at the 
beginning of Braak stage 3, the motor symptoms are not yet  apparent, but 
the SN pathology has started.  That t imeline also matches with the 
reported pre-motor striatal dopamine depletions. Hence, we believe that 
this model might in fact mimic the symptomology of early Braak stage 3 
or late Braak stage 2.  Based on the dopamine depletion and lack of motor 
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deficits,  three weeks was chosen as the time -point for the studies 





Figure 37: 3WKPD rats did not exhibit any deficits in the elavated beam walk test in terms of the time to corss the beam 
(A) and number of slips (B). 




Figure 38: Immunohistochemistry results. (A) Average TH-staining intensity in the CPu; (B) Number of TH-stained cells in the 







Figure 39: Gait analysis results in unlesioned controls and rats at 2, 3 and 4 weeks post 6-OHDA lesions. Significant 
gait changes are observed in the 4 weeks post 6-OHDA lesion group compared to unlesioned control group in Stride 
duration (A), stride length (B), stride frequency (C) (*p<0.005 maximum). Other gait parameters including 
percentage of the stride duration spent in breaking position (D), percentage of the stance in breaking position (E), 
and paw area at peak stance (F) did not have any significant differences between the groups.  
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Chapter 5. Aversion changes in PD1 
Rational 
Emotional alterations appear to be among the more critical features of 
the non-motor deficits in PD. Deficits  in recognition of facial  expressions 
of various emotions like anger  (Clark et al. ,  2008; Kan et al. ,  2002; 
Sprengelmeyer et al . ,  2003) , surprise (Clark et al. ,  2008),  happiness  
(Clark et al. ,  2008) , fear (Clark et al. ,  2008; Sprengelmeyer et al. ,  2003) ,  
sadness (Ariatti  et al. ,  2008; Clark et al. ,  2008; Sprengelmeyer et al. ,  
2003) and disgust  (Kan et  al. ,  2002; Sprengelmeyer et  al. ,  2003; Suzuki 
et al. ,  2006) ,  have been reported in Parkinson‘s disease (PD). In a model 
of facial expressions of different em otions, Suzuki and others (Suzuki et 
al. ,  2006) have shown that PD patients have significantly lower 
sensitivity scores to disgust ,  but retain their sensitivity to other 
emotions. Results by Bowers and colleagues (Bowers et al. ,  2006)  also 
demonstrated reduced startle reactivity and lower self reported arousal 
during exposure to aversive pictures in early to midd le stages of PD, 
compared to age matched controls .  These reports  suggest lower 
sensitivity to disgust and aversion in clinical PD patients. Sprengelmeyer 
and colleagues have reported significant deficit  in disgust recognition in 
un-medicated PD patients ,  but not in medicated PD patients, leading 
researchers to speculate that disgust recognition deficit  could be a result 
of lower levels of dopamine  (Sprengelmeyer et al. ,  2003) . In addition,  
converging evidence links basal ganglia pathologies with alterations in 
aversion (Hayes et al . ,  2007; Mitchell et al. ,  2005; Montagne et al. ,  2006; 
                                                          
1 Results of this study have been published in Rane P, King JA. Exploring aversion in an animal 
model of pre-motor stage PD. Neuroscience 2011.. 
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Paulmann et al. ,  2009) . Basal ganglia pathology, as well  as,  reduced 
dopamine levels are reported in PD years before the onset of clinical 
motor symptoms (Burn et  al. ,  1992;  Gaig and Tolosa, 2009) . This has led 
to the hypothesis that the aversion deficits may indeed precede the motor 
deficits of  PD.  
The main brain regions implicated in disgust processing and aversion 
response generation include insular cortex, basal ganglia and amygdala. 
In general,  the insular cortex has been thought of as the main processing 
region of the aversive stimuli ,  including olfactory (Heining et al. ,  2003; 
Royet et al. ,  2003; von dem Hagen et al. ,  2009)  and gustatory (Small et 
al. ,  2003) stimuli,  pictures of facial expressions of disgust  
(Sprengelmeyer et al. ,  1998) , pictures of contamination (Wright et al. ,  
2004), as well as,  experience and imagination of disgust  (Jabbi et al. ,  
2008) in healthy human population. Also, inhibition of insular cortex has 
been shown to block taste aversion memory in rats (Desgranges et al. ,  
2009). Similarly, right ventral striatum, a part of the basal ganglia, is 
another region that has been shown to have significant diffe rential BOLD 
activation in response to disgusting odors in healthy human population s 
(Heining et al. ,  2003) , implying involvement of  ventral  striatum not just  
in recognition, but in the processing of disgust stimuli.  The third brain 
region, the amygdala, has been known to be involved in processing 
aversive stimuli and also in generating an appropriate behavioral 
response (Davern and Head, 2011; Reilly and Bornovalova, 2005) . 
Damage to the amygdala has shown to block aversion  (De Martino et al. ,  ;  
Ghods-Sharifi  et al. ,  2009) . Since pathologies of all three regions have 
been observed in PD at different stages of the disease (Alvarez-Erviti  et  
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al.,  ;  Burn et al. ,  1992; Kikuchi et al. ,  2001) , the observed behavioral 
deficits could be a result of dysfunction of either the aversion processing 
brain regions,  the response generating brain regions , or both.  
In this study we examined whether aversion deficits exist in the pre -
motor stages of PD by exploring the behavioral response of our rat model  
to the aversive odor of butyric acid (BA)  (Endres and Fendt, 2009; Fendt 
and Endres, 2008). As discussed in Chapter 4, this model demonstrates 
significant depletion of TH-positive neurons in the striatum and 
substantia-nigra, but lacks any significant motor deficit.  Hence,  any 
observed aversion changes would support the notion of these  changes 
preceding the motor deficits.  
The current study employed grooming behavior as a measure of arousal 
(Denmark et al. ,  2010; Homberg et al. ,  2002) . Self-grooming behavior is 
part of the process that may decrease arousal to restore the homeostatic  
status disturbed by anxiogenic and/or stressful stimuli (Gispen and 
Isaacson,  1981; Jolles et al. ,  1979; Kalueff  and Tuohimaa,  2005; 
Kametani,  1988). We also tested for any changes in avoidance of the 
aversive odor that might be a result of the 6-OHDA lesions. Additionally,  
BOLD fMRI was performed to look at corresponding chang es in neural 
activation.  
We hypothesized that the rats from the PD model group would exhibit 
lower aversion behavior. In addition, we proposed lower BOLD activation 
in response to aversive stimulus  would be seen in several brain regions 
associated with disgust processing and response generation in PD animals 





Adult male Long Evans rats (300 -350g,  N = 108) were obtained from 
Harlan Sprague–Dawley Laboratories (Indianapolis,  IN). Animals were 
randomly assigned to various studies as stated in Table 3. The animals 
were group-housed (2 per cage) in Plexiglas cages and maintained in 
ambient temperature (22–24°C) on a 12/12 h light/dark cycle. Food and 
water was provided ad libitum. All procedures were approved and 
monitored by the University of Massachusetts Medical School 
Institutional Animal Care and Use Committee . Surgeries on sham and 
3WKPD group were performed as described in Chapter 4. All tests were 
performed at 3 weeks past the last surgery.  
Study Group Number of rats per 
group 
Arousal Behavior test Control 16 
 Sham 16 
 3WKPD  16 
 
Avoidance behavior test Control 10 
 Sham 10 
 3WKPD 10 
 
fMRI Control 10 
 Sham 10 
 3WKPD 10 
Table 3: Rat assignment per different tests in aversion study. 
Arousal Behavior Test 
For avoidance behavior , rats were acclimated to an empty test cage, 
similar to a home cage without the bedding material,  for 5 minutes each ,  
on two days prior to the test day. On test day, rats had three additional 5-
minute acclimation trials with a setup similar to the one on the two 
previous days. However, during these sessions, there was an addition of 
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an unscented filter paper pad (2 
cm x 2 cm) in the cage (Figure 
40). Rats were allowed a one 
minute inter-trial break, during 
which the filter paper pad was 
removed from the cage. During 
the actual test,  the rat behavior 
was recorded for 5 minutes in the 
test cage with 10ul of butyric acid 
(99+%, Sigma-Aldrich) on a f ilter 
paper pad in one corner of  the cage lid.  The videos were later scored for 
grooming time and duration of  approach behavior to the scented pad.  
Avoidance Behavior Test 
The avoidance behavior test was based on a test by Endres and Fendt 
(Endres and Fendt,  2009) . The test arena was a 90cm x 90cm black 
Plexiglas arena. An overhead camera with Ethovision software (Noldus 
Information Technology, Leesburg, VA) was used to score the behaviors.  
Four corner zones of 30cm x 30cm each were virtually marked using the 
software. Each of the four corners contained one 2cm x 2cm filter paper 
pad. Rats were acclimated for 5 minutes one day prior to the test day. On 
the test day, each rat was taken out of the home cage and placed in a 
holding cage for 2 minutes.  They were acclimated to the arena again for 2 
minutes and brought back to the holdin g cage. The rats then performed 4 
trials of 5 minutes each in the arena . During each trial,  they were allowed 
to explore the arena freely,  while 10ul of  BA was added to one of the four 
zones while the other 3 were left unscented. The odor  zone was chosen 
Figure 40: Arousal behavior test. 10µl of butyric odor was 
presented on a 2 cm x 2 cm filter paper pad. The rat’s 
behavior is recorded for 5 minutes. The videos were scored 
later for time spent grooming and time spent exploring the 
filter paper pad. 
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randomly, but included 
one trial each per 
corner as the odor 
corner to eliminate the 
effect of corner 
preference. Rats 
performed two sessions 
of two consecutive 
trials each, with a 2 
minute rest  period 
between the trials in a 
holding cage. Between 
the two sessions, the 
rats spent 20 minutes 
in the home cage to 
eliminate any stress 
related to long test periods. The track from each trial was analyzed for 
approach frequency and t ime spent in each of the four zones.  
Functional MRI 
Functional MRI was performed on awake rats  as described by King et.  
al.  (King et al. ,  2005) . The setup consisted of a head holder body tube  
combination in order to secure the rat with a surface coil –  volume coil  
combination for Imaging. Rats were anesthetized with isoflurane and 
restrained in the head holder and body tube set up. Effects of isoflurane 
wore off before the imaging session .  EMLA cream, a local anesthetic,  was 
used to relieve any discomfort  associated with the head holder. Rats were 
Figure 41: Schematic representation of avoidance behavior test. The test 
was conducted in a 90cm x 90cm black Plexiglas arena, virtually divided 
into four 30cm x 30 cm corner zones. At the four corners, four 2cm x 2cm 
filter paper pads were attached to the bottom of the area using a double 
sided adhesive tape. Each rat performed four 5 minute trials. During each 
of the trials, 10ul of Butyric acid was added to one of the corners chosen at 
random. The red square represents presence of scent in one of the 
corners. The blue squares represent the corners with blank filter paper 
pads. The rat’s behavior was recorded using an overhead camera and 
behavior was analyzed using Ethovision software (Noldus Information 
Technology, Leesburg, VA) 
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acclimated to this setup for 9 
days prior to the imaging 
session. A previous study in our 
lab has shown that repeated 
acclimation reduces the stress  of  
imaging.(King et  al. ,  2005)  
Functional MRI was performed 
on 4.7T/40cm horizontal bore 
magnet (Oxford, UK)  with 20 
G/cm magnetic field gradients and Bruker Biospec console (Bruker,  
Germany). A 1H dual coil system (Figure 42,Insight NeuroImaging 
Systems, Worcester,  MA) with a transmitting volume coil and a surface 
receiving coil was used for imaging.(Ludwig et al. ,  2004)  All of the 
images were acquired over a 32 mm x 32 mm FOV and included 18 1mm 
slices. The scanning session included one anatomical and one single 
functional scan. The anatomical scan was acquired using multi -slice spin 
echo (RARE) sequence with matrix size of 256 x 256, RARE factor = 8, 
repetition time (TR)=2125 ms, effective echo time (TE) = 50 ms and 4 
averages .  The functional scan was acquired using Gradient -Echo Echo 
Planar Imaging sequence with matrix size = 64×64  (0.5 x 0.5 mm 
resolution), TR=1 s,  TE = 30ms, f lip angle = 60 ◦.  The functional scan 
included 180 repetit ions (NR) within the scan , with a total scan length of 
180 seconds. Rats were exposed to air  during the first  60 seconds and to 
10ul of  BA during the remaining 120 seconds.  
Figure 42: MRI imaging setup. Rat is secured at the teeth 
with a bite bar and a pair of ear plugs at the ears in the 
head holder. His body is restrained in a body tube. The 
head holder-Body tube combination is placed inside a 
surface coil – Volume coil MR imaging setup. Local 
anesthetic was applied to the rat’s ears to relieve any 
discomfort of this set up and rats were acclimated to this 





Arousal Behavior  
The videos from the arousal behavior test were scored for the total t ime 
spent grooming and approaching (rat ‘s nose within half of an inch from 
the pad) the filter  paper pad containing the odor. Any values fall ing 2 
standard deviations away from the group means we re eliminated from the 
final mean calculation. Univariate ANOVA with general linear model  was 
used to compare grooming times and approach times  between groups.  
Avoidance Behavior  
The aversion behavior tracks were analyzed for  frequency into different 
zones, total time spent in the zone, and time during each visit  to the 
different zones for  each of the 4 trials  per rat.  Tracks with values falling 2 
standard deviations away from the overall group means were eliminated 
from the final mean calculation. The 4 trials were averaged  per rat to 
obtain one set of  values per rat .  The results were compared between the 
control,  sham and 3WKPD groups using Repeated measures ANOVA with 
bonferroni correction for multiple comparisons. Two separate 
comparisons were done for zone frequencies  and zone times.  The 3WKPD 
group was then compared with the sham group to test the effects of 6 -
OHDA lesions on the avoidance behavior.   
Imaging Study  
Each fMRI scan was motion corrected using SPM8 software (Functional 
Imaging Laboratory,  London, UK). A region of interest (ROI) map was 
generated for each subject by registering their anatomical scan to a built -
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in, fully segmented rat brain atlas in Medical Image Visualization and 
Analysis (MIVA, http://ccni.wpi .edu/miva .html).  A code written in 
MATLAB (Mathworks Inc.,  Natick, MA, USA) generated percent blood 
oxygen level dependent (BOLD) maps with p<0.001  for every voxel in the 
64 x 64 x 18 volume. For each ROI,  the average BOLD value was 
calculated per subject by averaging all the voxels in the BOLD map that 
fell within the particular ROI.  BOLD fMRI activation values for olfactory 
bulb (OFB), anterior olfactory nuclus (AON), piriform cortex (PirC), 
nucleus accumbens (NAcc), Insular cortex (InsC), basal nucleus of 
amygdala (BNA), lateral nucle us of amygdala (LNA), central nucleus of 
amygdala (CNA) and medial  nucleus of  amygdala (MNA) were fed into 
SPSS for statistical analysis .  These ROIs were chosen a priori ,  based on 
their involvement in olfactory and aversion processing. Repeated 
measures ANOVA with bonferroni correction was used to compare the 
three groups. Additional univariate ANOVA  with bonferroni correction for 
multiple comparisons for was used to do pair-wise comparisons between  
groups for the percent BOLD signals  within different ROIs .  
Results 
During the 5 minute arousal behavior test,  all of the control,  sham and 
3WKPD groups spent equal time exploring the scent . The univariate 
ANOVA revealed no difference between the approach time (F ( 2 , 4 5 )=0.193, 
p=0.825), but there was a significant main group effect  in the grooming 
behavior (F ( 2 , 4 5 )=4.343, p<0.02). Post-hoc tests with bonferroni 
correction revealed significantly lower grooming in the 3WKPD group as 
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compared to sham (t ( 3 1 ) =2.52, p<0.05) and control  (t ( 3 1 ) =2.64, p<0.04)  
groups (Figure 43).  
 Repeated measures ANOVA with bonferroni correction for multiple 
comparisons for zone frequencies  in the avoidance behavior test revealed 
a significant main effect of scents (F ( 1 , 2 3 ) =26.858, p<0.001), but no group 
effect (F ( 2 , 2 3 )=0.266, p=0.769) and no scent x group interaction 
(F ( 2 , 2 3 )=0.666, p=0.524). However, there was a significant main effect of  
scent (F ( 1 , 2 3 ) =4.458,  p<0.05), significant main effect of group effect 
(F ( 2 , 2 3 )=4.615, p<0.03), qualified by significant scent x group interaction 
(F ( 2 , 2 3 )=4.918, p<0.02). The repeated measures ANOVA between control 
and sham grouups indicate that,  there were no significant differences 
between the two groups  (Figure 45). There was a significant main effect  
of scents (F ( 1 , 1 3 )=22.309, p<0.001) in the relative frequencies to the BA 
zone versus the no-scent zones (Figure 45A), confirming that both, the 
Figure 43: Arousal behavior test results. Significantly lower grooming in the 3WKPD group as compared to sham 




controls and the shams, treated the BA zone differently than the no-scent 
zones,  and there was an overall increase in frequency to the BA zone . 
There was no significant group effect  or scent x group interaction 
(F ( 1 , 1 3 )=0.009, p=0.927). The total time spent by the rats in the different 
zones (Figure 45B) had a main effect of scent (F ( 1 , 1 3 ) =81.407, p<0.001) 
and no significant scent x group interaction (F ( 1 , 1 3 )=0.481, p=0.499) 
among the control and sham groups . 
The hypothesis that the 3WKPD rats would have deficits in avoidance 
was tested by comparing their  performa nce with the sham lesioned rats,  
using repeated measures ANOVA  (Figure 46). The 3WKPD rats did not 
have any significant main group effect  (F ( 1 , 1 7 ) =0.308, p=0.586) in the 
zone frequencies as compared to shams  (Figure 45A), but there was a 
significant main effect of scents (F ( 1 , 1 7 ) =19.53, p<0.001). This implied 
that,  irrespective of the group  that they belonged to , rats treated the BA 
zone differently from the no -scent zone.  Both groups had relatively higher 
frequencies to the BA zone compared to  the no-scent zones (Figure 46A). 
The repeated measured ANOVA of the total zone t imes in the BA versus 
no-scent zones between the sham and 3WKPD groups (Figure 46B) 
revealed a significant overall group effect (F ( 1 , 1 7 )=4.92, p<0.05), qualified 
by significant scent x group interaction (F ( 1 , 1 7 )=6.026, p<0.03). There was 
a lack of significant effect of scent (F ( 1 , 1 7 ) =0.872, p=0.363). Additional 
univariate analysis of BA zone time revealed that the time spent in the BA 
zone was significantly higher in the 3WKPD group as compared to the  
sham group (t ( 1 7 )  = 2.395, p<0.03).  
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Analysis of BOLD activation in ROIs based on a priori  hypothesis 
revealed a significant group x ROI interaction (F ( 1 6 , 1 4 4 )=4.97, p<0.001).  
Lack of significant group effect (F ( 2 , 1 8 ) =3.109, p=0.069) indicated that 
there were no significant difference between the overall BOLD activation 
between the groups.  Additional univariate analysis with bonferroni 
correction revealed that all the groups had similar activation of the 
olfactory system (F ( 2 , 2 2 )=0.601, p=0.557 for OFB;  F ( 2 , 2 2 ) =0.9, p=0.42 for 
AON; and F ( 2 , 2 2 )=0.068, p=0.935 for PirC; Figure 47A). Among the post 
processing areas, NAcc (F ( 2 , 2 2 )=2.374,  p=0.118) and InsC (F ( 2 , 2 2 )=1.018,  
p=0.377) did not reach significance either (Figure 47B). But the 3WKPD 
group had significantly lower positive BOLD activation in the sub-regions 
of the amygdala such as CNA(F ( 2 , 2 2 ) =8.418, p<0.002),  BNA (F ( 2 , 2 2 )=8.629,  
p<0.002) and LNA (F ( 2 , 2 2 )=8.672, p<0.002) (Figure 47B) compared to 
controls and sham lesioned rats ,  while the MNA did not reach 
significance (F ( 2 , 2 2 ) =0.84, p=0.446).   
 
A B 
Figure 44: Comparison of all three groups. Frequencies to BA zone versus no scent zones (A) had a significant main effect 
of scent (F(1,23)=26.858, p<0.001) but no effect of group; Zone times (B) had a significant main effect of scent 
(F(1,23)=4.458, p<0.05), as well as, a significant main effect of group effect (F(2,23)=4.615, p<0.03), qualified by significant 





Figure 46: Avoidance behavior: Sham versus 3WKPD comparisons. Shams and 3WKPD responses were compared using 
ANOVA for repeated measures using general linear model. For the zone frequencies (A), there was a significant main 
effect of scent (F(1,17) = 22.309, p<0.001) but no significant group effect (F(1,17)= 0.758, p=0.396) implying similar recognition 
of presence of the butyric acid (BA) odor in one of the scents. There was a significant main effect of group (F(1,17)= 4.92, 
p<0.05) as well significant scent to group interaction (F(1,17)= 6.026, p<0.03) for total zone times (B). Further investigation 
of the time spent in butyric acid zones indicated a significant difference between the two groups (t(17)= 1.77, p< 0.03). 
A B 
Figure 45: Avoidance behavior: Control versus Sham comparisons. Shams and controls responses had no significant 
differences as indicated by ANOVA for repeated measures using general linear model with respect to frequencies to 
butyric acid (BA) zone versus no-scent zones (A), and Total time spent in BA zone versus no-scent zones (B). There was a 
significant main effect of scent in both the comparisons (F(1,13) = 22.309, p<0.001 for zone frequencies; F(1,13) = 81.407, 





Figure 47: Functional MRI results upon exposure to butyric acid. (A) Percentage BOLD activation in the olfactory 
system. (OFB, olfactory bulb; AON, anterior olfactory nucleus and PirC, piriform cortex); (B) Percentage BOLD 
activation in the post-processing areas. (NACC, nucleus accumbens; BNA, baso-nucleus of amygdala; LNA, lateral 
nucleus of amygdala; CNA, central nucleus of amygdala; MNA, medial nucleus of amygdala). (*CNA(F(2,22)=8.418, 






These studies showed that ,  in a rat model of pre-motor PD, produced 
through the utilization of stepwise 6 -OHDA lesions of the CPu, there was 
significantly lower arousal to the aversive BA odor . However, there was  
no significant difference in the arousal response by the sham group 
compared to controls.  Additionally,  the sham and control rats exhibited 
equivalent avoidance of the butyric acid smell as exhibited by lower time 
spent in the corner with the BA odor in the avoidance behavior t est.  A 
comparison of the 3WKPD rats with the sham lesioned rats  accounted for  
the effects of the surgical procedure, and indicated a group dependent 
response,  that is ,  the rats‘  reactions to the BA zone versus no -scent zones 
were dependent on whether they belonged to the sham group or the 
3WKPD group. Higher time spent with the aversive odor by the 3WKPD 
group implied a diminished avoidance of aversive odor  compared to the 
sham group. These results parallel the observations noted in early stages 
of human PD, where PD patients exposed to aversive pictures exhibit  
blunted reactivity and report less arousal as compared to controls,  in 
spite of  recognizing the negative/aversive nature of those pictures 
(Bowers et  al. ,  2006; Sprengelmeyer et al . ,  2003) .  
One of the possible explanations of l ower grooming and lower avoidance 
is that PD rats fai led to smell the aversive odor , as olfactory deficits are 
common in pre-motor PD. However, the lack of difference in the 
exploratory behavior between the groups in the arousal and avoidance 
behavior tests,  along with equivalent  BOLD activation of the olfactory 
system in the fMRI study, do not support this premise .  Furthermore, it  is  
important to note that ,  hyposmia in the pre-motor phase of PD in human 
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studies has been reported to be selective of odors and concentrations.  
Therefore, it  is not a uniform loss of olfaction across all scents (Berendse 
and Ponsen,  2009; Ponsen et  al. ,  2004) .   
Another possible consideration to  address the behavioral deficits in 
aversive behavior in the PD rat model is the role of brain regions that 
process aversive stimuli including Insula r cortex, Nucleus Accumbens  and 
Amygdala complex.  Involvement of Insular cortex has been reported 
during aversion processing in human (Jabbi et al. ,  2008; Small et al. ,  
2003; Sprengelmeyer et a l. ,  1998), as well as,  in rat studies (Desgranges 
et al. ,  2009). Our results did not indicate any differences in the insular 
cortex activation between groups, which might have been  a contributing 
factor to the observed deficits in the behavioral responses . This result  is 
in accordance with the disease stage -dependent hypoperfusion of insular 
cortex observed in human PD patients where there is no significant  
difference between the cont rols  and early PD patients. (Kikuchi et  al. ,  
2001) 
The NAcc is also associated with aversion processing and plays a critical  
role in integrating excitatory (D1) and inhibitory (D2) inputs from 
Ventral Tegmental Area (VTA)  (Carlezon and Thomas, 2009). While the 
VTA itself has a uniform response to both rewarding and aversive stimuli,  
the NAcc neurons respond selectively, with either an inhibitory response 
to rewarding stimuli or an excitatory response to aversive stimuli.  
(Roitman et al. ,  2005)  Hence, NAcc neurons are believed to be involved 
in attaching valance to a stimulus by either selective activation or 
inhibition of neurons. (Carlezon and Thomas, 2009; Roitman et al. ,  2005; 
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Schoenbaum and Set low, 2003) We observed positive BOLD activation in 
NAcc in controls,  shams and 3WKPD rats,  without any significant group 
effect.    
The current results  point towards a probable dysfunction in the link 
between processing the aversive st imuli  and generating the appropriate 
response in PD rats.  The amygdala region, which is known to process 
emotions and generate the response cascade to stressful/aversive stimuli,  
had an overall lower positive BOLD activation in PD. When selective 
nuclei in the amygdala, medial  (MNA), basal (BNA), lateral  (LNA) and 
central (CNA) nuclei,  were examined individually,  significantly lower 
BOLD activation was observed in the BNA, LNA and CNA of PD rats  
compared to both sham lesioned and control rat s.  
The amygdala complex comprises of a multi-level system that  
orchestrates both sensory input and output. In regards to olfaction, the 
MNA is thought to receive inputs from accessory olfactory bulb (Davern 
and Head, 2011); inhibition of baso-lateral amygdala has been shown to 
result in impairment of conditioned olfactory aversion  (Desgranges et al. ,  
2008); and CNA thought to mediate behavioral response to aversive 
stimuli  (Finn et al. ,  2003) . Given the results of our studies, we speculate 
that the MNA, which serves as the input to the amygdala complex,  is  
functional in the PD rats while the BNA, LNA and CNA, which orchestrat e 
the response, might  be impacted. Hence, it  appears that the behavioral  
deficit  shown by PD rats in our study is mainly a result of deficit  in 
generation of an appropriate response to the aversive stimulus and not 
due to the inability to process the stimu lus. Our results are in accordance 
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with those by  Bower‘s and colleagues who  have reported blunted aversive 
reactivity among PD patients that  was attributed to amygdalar 
dysfunction as a result of suppression of the amygdala by the cortical  
regions (Bowers et al . ,  2006) .  
Since the sham lesioned animals did not exhibit any arousal or  
avoidance deficits  as compared to  the control animals in the behavioral  
tests,  as well as,  in the functional MRI experiment; we conclude that the 
observed deficits in the 6-OHDA administrated rats cannot be attributed 
to the stress of the surgery but to changes in  dopamine levels.   
To date, loss of aversion in humans PD patients has been reported in the 
early to middle stages of PD.  However ,  the current study has provided 
additional insight into the fact that these deficits might indeed be present 
in the pre-motor stages as well.  Since the human reports are based on 
exposure to facial  expressions of  disgust or photographs of mutilation 
and contamination,  future studies need to address potential  olfactory 
aversion in humans with PD. We believe that such studies may provide an 
additional non-motor marker for testing pre-motor stage PD.  
Conclusion 
Taken together, our results show that the rat  model of pre -motor stage 
of PD exhibits lower arousal to aversive odor as compared to controls and 
fails  to demonstrate avoidance of the aversive odor. These results might 
be comparable to reports in human PD patients in early stages of the 
disease exhibiting decreased arousal and blunted startle reactivity in 
response to aversive stimuli.  Further, our functional MRI results support 
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the hypothesis that the observed behavioral deficits are not a result of  
deficits in olfactory recognition but are most likely caused by deficits in 




Chapter 6. Cognitive deficits in PD 
Rational 
Co-morbid cognitive deficits are reported in PD patient population with 
a prevalence rate of approximately 40% at  stage 1 to 86% at  stage 4 
(Growdon et al. ,  1990) . Reports confirm estimates of cognitive decline in 
upwards of 14%  per year of these patients (Galvin, 2006) . The early 
deficits appear to mainly c onsist of cognitive functions that are 
associated with the frontal lobe(Gotham et al. ,  1988)  and frontal-striatal  
pathways(Alexander et al. ,  1986; Monchi et al. ,  2007) ,  which are 
pathways sub-serving attentional set-shifting, working memory and 
executive function (Adler, 2005; Cools et al. ,  2001; Downes et al. ,  1989; 
Sharpe, 1990; Sharpe, 1992) . Hawkes and colleagues  have hypothesized 
that the cognitive deficits may exist  as early as  in Braak stage 2 of  PD 
(Hawkes et al. ,  2010) . The goal of this study was to test the possibility of 
pre-motor executive function deficits  in PD.  
Sodium butyrate as a possible treatment for PD 
This study explored the potential of sodium butyrate (NaBu), a drug 
from the histone deacetylase inhibitor (HDACi) family of  drugs, as a 
therapeutic  agent to mitigate  the pre-motor cognitive deficits in PD. Even 
though dopamine plays an important role in multiple neuronal networks 
involved in cognition (Nagano-Saito et al. ,  2008; Winter et  al. ,  2009) , 
dopaminergic  therapeutic agents, proven to relieve the motor symptoms 
of PD, are not always effective at alleviating the co -morbid emotional and 
cognitive symptoms (Downes et al. ,  1989; Gotham et al. ,  1988; Jubault et  
al. ,  2009). Drugs from the HDACi family have been shown to be useful in 
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multiple psychiatric  and neuro -degenerative disorders (Sadri-Vakili  and 
Cha, 2006; Schroeder et al. ,  2007; Tsankova et al. ,  2006)  and have 
neuroprotective effects in an in-vitro model system, as well as,  in in-vivo 
studies (Ferrante et  al. ,  2003; Gardian et al. ,  2005; Gray and Dangond, 
2006; Hockly et al. ,  2003; Ryu et al. ,  2003; Wu et al. ,  2008) .  Emerging  
evidence of reversal  in contextual memory deficits in a mouse model of 
Alzheimer‘s disease (Kilgore et al. ,  2009)  and improvement in learning 
and long-term memory in toxin-induced, as well  as,  genetic  mouse models 
of cognitive deficits (Fontan-Lozano et al . ,  2008)  point to a potential role 
of HDACis in neurocognition. Indeed,  since this class of  drugs is well-
tolerated by humans and rodents, there may be a strong translational 
validity (Hoshino and Matsubara, ;  Liu et  al. ,  2006) .  
Methods 
Animals 
Adult male Long Evans rats (300 -350g,  N = 32) were obtained from 
Harlan Sprague–Dawley Laboratories (Indianapolis,  IN). The animals 
were group-housed (2 per cage) in Plexiglas cages and maintained in 
ambient temperature (22–24°C) on a 12/12 h l ight/dark cycle. They were 
provided with food and water ad libitum. All procedures were approved 
and monitored by the University of  Massachusetts Medical School 
Institutional Animal Care and Use Committee . Rats were randomly 
divided into controls,  sham lesion, 6 -OHDA lesion (3WKPD) or 6-OHDA 
lesion with NaBu treatment (3WKPD+N aBu) groups as described in Table 
4. Surgical procedures were similar to those described in Chapter 4. All  
the groups were tested three weeks  post lesion.  
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Study Group Number of rats per 
group 
ED/ID test Control 8 
 Sham 8 
 3WKPD  8 
 3WKPD + NaBu 8 
Table 4: Rat assignment per different groups in executive function test. 
Extra dimensional/Intra dimensional set shifting test 
Executive functioning was tested using the rat analog  of the Wisconsin 
Card sorting test called the Extra-Dimensional / Intra-Dimensional set  
shifting test (ED/ID test)(Birrell and Brown, 2000) . The test apparatus 
(Figure 48A) consisted of a custom -built  black Plexiglas arena (90cm x 
90cm). A removable divider separated test area from the initial holding 
area at the other end. Test area was divided into two additional sections  
(Areas A and B) using a black partial divider. These areas were identified 
with a spotlight over a paper plate f il led with bedding. Throughout the 
Figure 48: (A) ED/ID test setup. Dotted line represents temporary divider separating test area from the initial holding 
area. Areas A and B, separated by a partial divider (solid brown line), contained paper plates filled with bedding 
material. One of the plates contained the food reward that the rat could retrieve by digging into the bedding 
material. The rat had to dig into the correct plate to successfully complete a trial and retrieve the reward. (B) ED/ID 
shift behavioral paradigm. The colors represent the different colored lights (one dimension) and the numbers 




test,  stimuli  from two dimensions ( lights/odors) were used. The light 
dimension included pairs of lights (orange versus blue, purple versus 
yellow or green versus red) , while the odor dimension consi sted of pairs 
of different aromatic oils (100ul) mixed with a plate of bedding (vanilla 
versus lemon, peppermint versus thyme or rosemary versus cinnamon).  
The test day was set  at 3 weeks post second lesion. To prepare for this 
test,  four days before the test day, rats were individually housed and 
maintained on a restricted diet (15 grams of pellets/day) . They were 
habituated to the Plexiglas arena and trained in the home cages to find 
reward (pieces of rat chow)  hidden in paper plates fil led with bedding.  
Similar paper plates fil led with bedding with or without the reward were 
presented to the rat during testing.   
On the test day each rat randomly started with either the l ight or the 
odor dimension as the init ially relevant dimension (IRD) and the other 
dimension initia lly irrelevant dimension (IID). Tests included simple 
discrimination (SD), compound discrimination (CD), intra -dimensional 
shifting (ID), and extra-dimensional set shifting (ED).  Figure 48B 
describes the set of stimuli for different tasks.  The tasks were always  
performed in the order of SD, CD, ID and then ED. This is critical  because 
the performance in the subsequent task was dependent upon the 
completion of the preceding task. The rat  started each trial in the holding 
area. As a trial began, the temporary divider separating the test area and 
the holding area was removed and the rat was allowed to explore the 
arena freely. During SD, rats had to discriminate between only one set of 
stimuli from the chosen dimension, I RD. The reward was associated with 
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one of  the stimuli  from the IRD. During SD, the IID was absent.  For CD, 
reward was associated with the same stimulus as in SD , while a second set  
of stimuli from IID were introduced.  IID stimuli  needed to be ignored by 
the rat in order to complete the task successfully.  ID was similar to CD 
but with a complete new set of stimuli from the IRD , as well as,  the IID. 
Finally,  during ED a  whole new set of stimuli from both, the IRD and the 
IID, were introduced, but this time the reward was associated with one of  
the stimuli from the IID. Each time the rat completed a trial  successfully  
by digging into the plate associated with the reward stimulus, he was 
allowed to continue digging until he retrieved the reward. If he first dug 
into the plate associated with the non -reward stimulus, he was picked up 
and returned back to the holding area with that trial  marked as a failed 
trial;  and a whole new trial  then started. Each of the four tasks was 
marked as completed when the rat success fully completed six consecutive 
trials  during that task.  
Treatment 
The 3WKPD+NaBu group received daily intra -peritoneal injections of 
NaBu treatment (250 mg/kg/ml in 0.9%saline; Sigma Aldrich, St.  Louis, 
MO) starting at 2 week post surgery for 5 days duri ng the dark phase of  
the light/dark cycle.  The NaBu solution was prepared fresh at the start of 
the treatment. Treatment ended 2 days prior to the test day in order to 
minimize stress.  
Data analysis 
The total number of trials to successful completion of ea ch task was 
noted. Repeated measures ANOVA with bonferroni correction for multiple 
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comparisons was  used to analyze the group and task effects  using SPSS 
(IBM Corp.,  Somers, NY). The groups were further compared with each 
other within individual tasks using  univariate ANOVA with bonferroni 
correction. For each group, the effect of task difficulty was analyzed using 
repeated measures ANOVA on individual group results.  Finally,  to analyze 
the effects  of NaBu treatment on attention after 6-OHDA lesions, 3WKPD 
group was compared with 3WKDP+NaBu group in the SD and ID tasks 
using repeated measured ANOVA.  
Results 
Repeated measures ANOVA revealed a significant main effect of task 
(F ( 9 , 8 1 ) =31.729,  p<0.001) , as well as,  a significant main effect of group 
Figure 49: Response of control, sham lesioned, 3WKPD and 3WKPD + NaBu treatment groups in 
simple discrimination (SD), compound discrimination (CD), intra-dimensional shift (ID) and extra-
dimensional set shifting (ED) tasks. There was a significant main effect of task (F(3,81)=31.73,p<0.001), 
as well as, a significant main effect of group (F(3,27)=5.786,p<0.004), qualified by significant 
interaction (F(9,81)=7.651,p<0.001). There was no significant difference between the number of trials 
needed to complete SD and CD tasks. However, there was an overall increase in the number of trials 







(F ( 3 , 2 7 )=5.786, p<0.004) qualified by significant group x task interaction 
(F ( 9 , 8 1 ) =7.651, p<0.001)  as shown in Figure 49.  Overall,  there was no 
significant difference between the number of trials needed to complete SD 
and CD tasks (t ( 2 7 )=0.13, p=1.0). However, there was an increase in the 
number of tr ials needed to complete ID compared to SD (t ( 2 7 )  = 3.51, 
p<0.01) and CD (t ( 2 7 )=4.08, p<0.003) tasks. The ED task requireded an 
even higher number of trials to get to completion as compared to SD 
(t ( 2 7 )=6.79, pp<0.001), CD (t ( 2 7 )=9.71, p<0.001) and even ID (t ( 2 7 )=4.63, 
p<0.001) task, indicating a progressive increase in diff iculty level  across 
the tasks.  
The within task univariate analysis  revealed that there was no 
significant effect of  group during the SD (F ( 3 , 2 7 )=2.02, p=0.135) and the 
CD (F ( 3 , 2 7 )=0.319,  p=0.811) tasks. There was a significant main effect of 
* 
* * # 
Figure 50: Univariate analysis of within task comparisons revealed a significant decrease in number 
of trials needed by the NaBu treatment group as compared to sham lesioned and 3WKPD groups. 
The 3WKPD groups needed significantly higher number of trials to complete the ED task as compared 
to all the other experimental groups. (*p<0.001, #p<0.02) 
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group (F ( 3 , 2 7 )=10.388, p<0.001) during the ID task  (Figure 50). The post-
hoc tests revealed that the NaBu treatment group needed significantly 
lesser number of trials as compared to the sham (t ( 1 4 ) =4.93, p<0.001) and 
the 3WKPD (t ( 1 4 )=4.67, p<0.001) groups, implying a probable 
improvement in attentional set formation in the treatment group . 
Significant main effect of  group was observed in the ED (F ( 3 , 2 7 )=10.312, 
p<0.001)  task as well.  3WKPD group needed significantly higher number 
of trials as compared to controls (t ( 1 5 )=4.72, p<0.001), sham lesioned 
(t ( 1 5 )=3.31, p<0.02),  as well as,  the 3WKPD+NaBu group (t ( 1 4 )=4.85,  
Figure 51: Controls (A) need significantly higher number of trials for ED task compared to CD task (*p<0.03). Sham 
rats (B) need significantly higher number of tasks to complete ID and ED tasks as compared to SD and CD tasks 
(*p<0.02, **p<0.007).  The 3WKPD rats (C) needed higher number of trials to complete ED not just compared to SD 
(**p<0.002) and CD (** p<0.001), but also compared to ID task (#p<0.05). Similar to shams, 3WKPD rats had 
significantly higher number of trials in ID as compared to SD and CD tasks as well (*p<0.04). The NaBu treatment 





p<0.05) as per the post-hoc tests  (Figure 50).  
The within group repeated measures ANOVA revealed that for the 
control group (Figure 51A), there was a significant effect  of task on the 
number of trials needed to complete the four tasks  (F ( 3 , 2 1 )=4.11, p<0.02) 
with a significant difference between the CD and ED tasks (t ( 1 5 )=4.11, 
p<0.03). The sham lesioned rats (Figure 51B) exhibited a main effect of  
task (F ( 3 , 2 1 )=18.12, p<0.001) with significantly higher number of trials to 
complete the ED task as compared to bot h the SD (t ( 1 5 )=6.3, p<0.003) and 
CD (t ( 1 5 ) =4.5, p<0.02). The sham rats also needed significantly higher 
number of trials to complete the ID task as compared to the SD 
(t ( 1 5 )=5.42, p<0.007) and CD (t ( 1 5 )=7.49, p<0.002) implying a weaker 
attentional-set formation. Similar to the sham lesioned rats ,  the 3WKPD 
group (Figure 51C) also exhibited significant main effect of task 
(F ( 3 , 2 1 ) =34.26,  p<0.001) with significantly higher number of trials  for the 
ID and ED tasks as compared to both the SD (t ( 1 5 )=8.25, p<0.001 with ID; 
t ( 1 5 )=6.66, p<0.002 with ED)and CD (t ( 1 5 )=3.98, p<0.04 with ID; 
t ( 1 5 )=8.91,  p<0.001 with ED)  tasks. In addition there was also a 
significant difference between the trials  needed to complete the ID and 
the ED tasks (t ( 1 5 ) =3.76, p<0.05) implying a weaker attentional-set 
formation as compared to controls ,  as well  as,  a set-shifting deficit.  
On the other hand, the 3WKPD+NaBu group (Figure 51D) did not 
exhibit a task effect in completing the four tasks  (F ( 3 , 1 8 ) =2.244, p=0.118) . 
This might be indicative of a stronger attentional set formation and 
better set-shifting abilities as a result of the treatment . Investigation of 
SD-CD-ID progression between 3WKPD and 3WKPD+NaBu groups using 
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repeated measures ANOVA revealed a significant task by group 
interaction (F ( 2 , 2 6 )=9.97, p<0.001) without any significant task or group 
effect.  
Discussion 
The four tasks in the ED/ID test are designed to test various aspects of 
executive function  including attention, rule acquisition, cognitive 
flexibility,  error correction and trouble shooting . The SD task tests the 
subjects‘  ability to accomplish reward association and learni ng. The CD 
task tests their ability to keep attention on the rule learnt in the SD task 
while ignoring the newly introduced irrelevant dimension stimuli.  In the 
ID task, the subjects ‘  ability to apply the rules from SD and CD to a new 
set of stimuli  is assessed. During the SD, CD and ID tasks,  the subjects 
develop an attentional-set with respect  to the relevant dimension as a 
whole, and develop learned -irrelevance towards the second dimension  
(Ng et al. ,  2007) . In the ED task, the subjects‘  need to revise the 
attentional-set,  learnt relevance and irrelevance ,  based on alteration in 
the feedback they receive  (Nagano-Saito et al. ,  2008; Ng et al. ,  2007) . 
This exercise, tests the cognitive f lexibility of the subject s.  Humans,  non-
human primates, as well as,  mammals such as sheep and rodents have all 
demonstrated successful complet ion of the four tasks (Fox et al. ,  2003; 
Morton and Avanzo,  2011; Owen et al. ,  1992) . Because of the increasing 
levels of difficulty, higher number of tria ls are needed for the ID and ED 
tasks as compared to SD and CD tasks (Birrell and Brown, 2000; Fox et  
al. ,  2003; Robbins et  al. ,  1996) .  
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The overall performance of the rats during the four tasks in the current 
study aligned with the previous observations of progressively increas ing 
difficulty levels  while moving from SD to CD to ID to ED tasks .  The 
control and the sham rats needed higher number of trials for completion 
of ID and ED tasks as compared to the first two tasks,  though the 
difference was not significant for ID in controls.  The 3WKPD rats also 
had similar performance, but needed significantly higher number of trials 
in the ED task as compared to ID task. Their performance in the first 3 
tasks was comparable to the performance by the control and the sham 
groups, implying a similar reward association, rule-learning and 
attentional-set  formation in the three groups. But the 3WKPD group was 
significantly weaker in the ED task, indicating a set -shifting specific  
deficit.  These results are in accordance with previous observations i n PD 
patients where set -shifting specific deficits have been reported  (Cools et 
al. ,  2003; Owen et al . ,  1992; Schneider, 2006) . The cognitive inflexibility,  
as depicted by deficit  in the  ED task, can be a result of  two phenomena,  
deficits in revising the relevance of IRD , or enhanced learnt  irrelevance 
towards IID, leading to the inability to attend to the dimension 
previously learnt as  irrelevant .  Owen‘s  group has shown that the ED 
deficit  in PD patients is more pronounced in the case of shifting attention 
to a dimension previously learnt as irrelevant,  hence enhanced learnt 
irrelevance being the contributing factor to the deficit  (Slabosz et al . ,  
2006). In their study, they observed that the PD patients were  indeed 
able to focus their attention away from the previously relevant dimension ,  
therefore the preservation of the learnt relevance did not appear to be a 
contributing factor to the PD deficit .  The tests in our study had the 
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complete-learnt irrelevance design in terms of the ED. Hence, our rats  
did exhibit deficits  in revising learnt irrelevance based on negative 
feedback they received after  incorrect trials .   However, this study 
paradigm does not test for deficits in revision of  IRD. Hence, additional 
testing with a completely novel dimension as the relevant dimension 
during the ED task would be able to delineate the exact cause of the 
observed ED deficit.  
We hypothesize that  the observed ED deficit  in 3WKPD rats might be a 
result of  an inability to learn  new rules as a result  of lowered dopamine 
levels disrupting PFC-striatal connectivity. This connectivity is  
hypothesized to be important for set shifting and is impacted in PD 
patients (Monchi et  al. ,  2004) . Dopamine depletion has been shown to 
cause disruption of  PFC -striatal  connectivity ,  as well as,  ED deficit  in 
healthy controls  (Nagano-Saito et al. ,  2008). Indeed, lack of similar 
deficits in sham lesioned rats in this study supports dopamine depletion 
as a cause; thus, eliminating the potential impact of stress of the 
lesioning process as a probable cause  for the ED deficit .   
While shifting from CD to ID task, both the 3WKPD and sham lesioned 
groups needed significantly higher number of trials,  as compared to their  
own performance in the CD task. A similar significance was missing in the 
control group. Even though the ID performance was not significantly 
different between the groups, the within group comparisons migh t be 
pointing towards a weaker attentional -set formation in the sham and the 
3WKPD groups as a result of the surgical procedure , irrespective of the 
dopamine depletion.  Cingulate cortex lesions have shown to result in ID 
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deficits in rats (Ng et al. ,  2007)  without any ED deficits .  As per our 
knowledge, our rats  do not hav e cingulate cortex lesions.  This is also 
supported by the fact that the deficits we observed are not in comparison 
with the controls as those observed by the Ng group . Additional research 
is needed to further analyze this observation of weakened attentiona l-set 
in our study.  
The performance of the 3WKPD+NaBu group in the ED task had 
significant improvement over the performance of the 3WKPD group, and 
was comparable to the performance by the control group.  Hence, NaBu 
appears to be effective in preventing th e deleterious effects of 6-OHDA. 
In addition, the 3WKPD+NaBu rats ,  as they performed SD, CD and ID 
tasks, were able to focus increasing amount of attention on the IRD and 
completely ignore IID. NaBu treatment has been shown to enhance 
reward association (Schroeder et al. ,  2008) . Hence, the NaBu treatment 
might have enhanced the reward association in our study,  leading to 
improved attentional set.  Additional experimentation is needed to 
confirm this hypothesis,  but was outside the scope of this particular 
study. However, results of this study point towards HDACis as a 
promising treatment option for cognitive deficits in PD.  
Conclusion 
Stepwise striatal lesions with low doses of 6 -OHDA in rats closely mimic 
the cognitive deficits observed in PD patients.  The observed deficits  are 
reported in post-clinical diagnosis stages in the patient population. Our 
results support the possibility of  the presence of these deficits in pre -
motor stages of PD as well.  NaBu ameliorates the cognitive deficits  
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resulting from striatal  dopamine depletion,  by significantly improving the 
cognitive abilities of the treatment group. By improving attentional set  
formation, as well  as,  set shifting ability,  the treatment of NaBu showed 
promising therapeutic potential to t reat pre-motor stage PD. Further 
studies may offer more insight into the cogniti ve enhancing effects of this 
class of  drugs.    
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Chapter 7. Resting State functional MRI 
Rational 
As described in Chapter 3 temporal correlations in low frequency 
fluctuations (<0.1Hz) in BOLD signals recorded in different brain regions 
can serve as  a measure of  functional connectivity between those 
regions.(Biswal et al. ,  1997)  Resting state (RS) connectivity during 
resting or passive task states has been observed in humans, primates, and  
rats (Biswal and Kannurpatti,  2009; Greicius et al. ,  2008; Pawela et  al. ,  
2008; Zhang et  al. ,  2010) .  
Thus, studying RS connectivity can further our understanding of how 
the brain functions by allowing us to map out complex neural circuits,  
referred to as intrinsic connectivity networks  (Shehzad et al. ,  2009) . 
Furthermore, the observed intrinsic networks have significant overlap 
with task-evoked activations  (Biswal et al. ,  1995; Fox et al. ,  2007;  
Greicius et  al. ,  2008)  and structural connectivity(Greicius et al. ,  2009; 
Hagmann et al . ,  2008) . RS connectivity, in turn,  allows us to observe how 
the brain‘s  functioning changes under different affected states. It  has 
been shown to change with various disease stages like Alzheimer‘s  
Disease (AD) (Lustig et  al. ,  2003; Rombouts and Scheltens, 2005) , 
Depression(Anand et al. ,  2005) , ADHD (Tian et al. ,  2006) , Multiple 
Sclerosis(MS)(Lowe et al. ,  2008; Lowe et al. ,  2002)  and even during 
normal aging (Andrews-Hanna et al. ,  2007) . In this study,  we analyzed 
the RS connectivity changes in our pre -motor rat model as compared to 
the age matched controls.  We hypothesized that,  6-OHDA lesions would 





hypothesized that  the RS observation might be able to delineate the 
beneficial effects of  NaBu on brain networks that resulted in enhanced 
cognitive performance in the treatment group.  
Methods 
Animals 
 Three groups of rats,  controls,  3WKPD, and 3WKPD rats with sodium 
butyrate treatment (3WKPD+NaBu) were used for this study. Table 5  
described the number of rats in the different groups. The 3WKPD and 
3WKPD+NaBu groups received 6-OHDA lesions of  10ug and 2ug each in 
1ul of vehicle as described in Chapter 4. The 3WKPD+NaBu group 
received daily intra-peritoneal injections of NaBu treatment (250 
mg/kg/ml in 0.9%saline; Sigma Aldrich, St.  Louis, MO) for 5  days during 
the dark phase of the l ight/dark cycle, starting at 2 weeks post surgery.  
The NaBu solution was prepared fresh at the start  of the treatment.  
Study Group Number of rats per 
group 
ED/ID test Control 10 
 3WKPD  13 
 3WKPD + NaBu 9 
Table 5: Assignment of rats to different groups in resting state connectivity study. 
Imaging 
Rats were anesthetized with isoflurane and restrained in the head 
holder and body tube set up. Isoflurane ‘s  effect  wore off  before the 
imaging session began. EMLA cream, a local  anesthetic,  was applied to 
relieve any pain associated with the head holder. Rats were acclimated to 
this setup for 9 days prior to the imaging session.  
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Gradient-Echo Echo Planar Imaging sequence with matrix size = 64×64 
(3.2cm x 3.2cm), 1mm slice thickness,  TR=1 s,  TE = 30ms, flip angle = 
60◦  was used to collect the resting state scans on 4.7T/40cm horizontal  
bore magnet (Oxford, UK) with 20 G/cm magnetic  field gradients and 
Bruker Biospec console (Bruker, Germany) using a 1H dual coil system 
(Insight NeuroImaging Systems, Worcester, MA). Fiv e to seven scans of 
200 repetitions each were collected per rat .  The goal was to achieve at  
least five scans per rat with minimal motion . Each repetition was a 
64x64x18 volume image of the brain.  
Data analysis 
Preprocessing of data 
All resting state fMRI f iles were motion corrected using SPM8 
(Functional Imaging Laboratory, London, UK) after discarding any scan 
with more than 0.5mm (1 pixel) motion. Areas outside the brain region 
were removed with hand drawn masks in MATLAB. All rats from all 
groups were al igned to one standard rat manually in MIVA. The 
alignment matrices were used to form aligned fMRI scans, which were  fed 
into the MATLAB based GIFT toolbox for independent component 
analysis for 30 components. The 30 overall mean components generated 
by GIFT were thresholded at z -scores > 1.65 (p<0.05) and compared with 
the rat brain atlas to choose 6 components as seeds for seed based 
connectivity. (Figure 52)  As compared to anatomical seed based ROIs,  
this method ensures a high correlation between the voxels  selected within 




Seed based connectivity analysis 
Each run of  the RS scans was spatially fi ltered using 4×4 Gaussian low -
pass filter with the standard deviation of 0.5 (FWHM=1mm). All time 
courses were 0.0018–0.1 Hz band-pass filtered and the first 10 images 
were discarded to ensure an equilibrium state. This frequency range has 
been shown to contribute towards cortical connectivity in brain in 
humans (Biswal et al. ,  1995; Cordes et  al. ,  2001) , as well  as,  in rats  
(Williams et al. ,  2006) . The cardiac and respiratory signals in humans are 
in the range of  0.6-1.1Hz and 0.1-0.5Hz, respectively (Cordes et al . ,  
2001). In rats,  the cardiac frequency is  of the order of  4 -5Hz and the 
respiratory frequency is of the range of ~1Hz (Majeed et al. ,  2009; 
Williams et al. ,  2006). The lower cutoff frequency removes any effects of  
magnet drift  from the correlation calculations. T he time courses for 
voxels within each of the seeds were averaged across the seeds to get  
averaged seed time courses (AST). Correlation coefficients  between each 
of the ASTs and time courses for individual voxels  were computed. The 
correlation values were averaged across each of the experimental groups 
in a pixel-by-pixel basis by removing any outlier pixel which had values 2 
standard deviations away from the group to form the seed based 
connectivity maps. The seeds that were chosen included olfactory bulb,  
prefrontal cortex, motor cortex, cingulate cortex, CPu, and amygdala. CPu 
was chosen as a seed because it  was our site of 6 -OHDA lesions. Amygdala 
was chosen because of the observed aversion deficits  seen in the 3WKPD 
group, and the known link between amygdala and emotional processing . 
The prefrontal cortex (PFC) and cingulate cortex were chosen based on 
their involvement in the cognitive processing.  Motor cortex was chosen 
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because we had observed a trend towards development of subtle motor 
deficits in our 3WKPD rats.  
For each seed, the correlation coefficient values for corresponding 
pixels were compared between groups using student‘s  t -test with p<0.005 
(corrected for false discovery rate of 0.05 for all the pixels that lie within 
the brain) and ttest  maps were generated. The pixels that significantly 
changed between controls and 3WKPD groups were averaged to plot the 
connectivity values. The values for the same pixels were also averaged in 
the NaBu treatment group to see if  NaBu was able to compensate for the 
changes in connectivity.  
Significance levels for between group comparisons were calculated 
based on the number of voxels within the brain that  were compared 
between the groups, by controlling for  a false discovery rate of 0.05,  
Figure 52: ROIs chosen for seed based connectivity 
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using Matlab. The significance levels used to compare the groups, based 
on seed regions were:  Amygdala (p< 0.0049), CPu (p< 0.0039), motor 
cortex (p < 0.0047),  PFC (p < 0.0028) cingulate cortex (p < 0.0050), and 
olfactory Bulb (p < 0.0032).  
Results 
Significant changes were observed in the RS connectivity of the various 
seeds tested during the analysis.  Two seeds that exhibited major 
differences between the PD and the contr ol groups were the motor cortex 
and the amygdala. The positive correlation between motor cortex ( Figure 
55, Figure 59C) and the majority of the brain had a significant increase in 
the PD rats as compared to controls.   The amygdala in controls had 
significant negative correlation with PFCs, cingulate,  motor and 
somatosensory cortices, as well as,  CPu and thalamus. The amygdala in 
PD rats lost this negative correlation and had  a weak positive correlation 
with those areas  (Figure 58, Figure 60C).  
However, the other seed regions had altered connectivity patterns as 
well.  Following is the list of several of  the altered connectivities.  For 
example, the olfactory bulb seed (Figure 53,Figure 59A) in the 3WKPD 
rats had a drop in positive correlation with the thalamus . The OFB‘s  
correlation with the amygdala had changed from negative in controls to 
positive in PD rats.  The OFB and lateral  PFC (prefrontal cortex)  also had 
significant increase in correlation between them in the PD rats compared 
to the controls .  Along with the increase in the connectivity with the OFB,  
the PFC in PD rats (Figure 54, Figure 59B) had a drop in positive 
correlation with the Thalamus compared to controls.  The negat ive 
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correlation between PFC and amygdal a, as observed in controls,  was also 
changed to positive correlation in PD. The cingulate cortex in PD rats had 
significantly lower positive correlation with the hippocampus and the 
thalamus,  while its  correlation wit h lateral PFC and hypothalamus 
increased as compared to controls ( Figure 56,  Figure 60A). The negative 
correlation between amygdala and cingulate cortex had also changed to  
positive correlation in PD rats.  The CPu (Caudate Putamen) correlation 
with the PFC, cingulate cortex, and hypothalamus was higher in the PD 
rats compared to the controls  (Figure 57, Figure 60B).  
The NaBu treatment was successful in restoring some of the correlation 
changes observed in PD rats back to their control levels.  Of particular 
notice were the motor and somatosensory cortices. However, any loss in 
the negative correlation in PD, as seen with the Amygdala and olfactory 
bulb, was not corrected by NaBu.  
Discussion 
Seed based RS connectivity ,  is thought to be a measure of  functional 
connectivity of that seed region with the rest of the brain. However, the 
echo-planner imaging technique, used to collect the RS fMRI scans during 
this study, can suffer from image distortions  (Buxton,  2002; McRobbie et 
al. ,  2003). Thus, an anatomical atlas based seed can, to some extent, have 
effects of surrounding regions in its  final connectivity map. We based our 
seeds on localized voxels with high z-score ICA components within 
various regions of interests (ROIs)  (Roy et al. ,  2009). Even though, the 
seeds only covered a part of  the ROI that they belonged to, the final 
connectivity map had a good representation of  the entire ROI .  This 
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indicated that ,  this technique might indeed be a better technique of seed 
selection than pure anatomical map based  seeds.  
The control rats in this study exhibited specific connectiv ity patterns 
based on seeds similar to those reported previously by our lab (Zhang et  
al. ,  2010). Observations in the 3WKPD rats supported our hypothesis 
that,  the 6-OHDA lesions would alter  the RS connectivity.  
One of the prominent changes observed in this study is the increased 
overall connectivity of the motor cortex.  Connectivity studies in human 
PD patients have shown increased connectivity of  the supp lementary 
motor cortices (Gatev et al. ,  2006; Wu et al. ,  2010) . Similarly, we also 
observed an increase in CPu connectivity with prefrontal cortices, 
cingulate cortex, and hypothalamus  in the 3WKPD rats compared to the 
controls.  These are in accordance with the observations by Kwak et al. ,  
who observed a significant increase in striatal connectivity with medial,  
inferior and orbital frontal  gyruses, as well as,  anterior cingulate cortex 
in unmedicated early-stage PD patients as compared to age matched 
controls (Kwak et  al. ,  2010) . The same study also reported a reduction in 
this hyper-connectivity with L-DOPA treatment known to increase 
dopamine levels in brain. Basal ganglia activity is modulated by 
dopamine,  and reduction in dopamine levels result  in oscil latory firing of 
neurons in the basal ganglia –thalamocortical circuitry , leading to 
increased synchronization between those regions (Gatev et  al. ,  2006) . 
Gatev has also hypothesized that the tremors observed in PD might be 
linked to this increase in basal ganglia oscillations  and neuronal 
synchrony (Gatev et  al. ,  2006) . This is  interesting because, even though 
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our 3WKPD rats did not exhibit any significant motor deficits,  they 
exhibited a trend towards development of shuffling gait as observed in PD 
patients, and the rats at 4 week post 6 -OHDA lesions, indeed exhibited 
gait similar to PD. Hence, our observations of increased CPu and motor 
cortex connectivity might be indicative of eminent onset of motor 
deficits.  
Another major difference observed between the control and the PD 
group, was the loss of  negative correlation between the amygdala and 
CPu, motor cortex, PFC, cingulate cortex and olfactory bulb in the PD 
group. Significant negative correlation has been reported between the 
baso-lateral amygdala and prefrontal cortex in healthy subjects (Roy et  
al. ,  2009). These regions are thought to be important in response 
expression and in facilitation of   attention to salient  stimuli  (Roy et  al. ,  
2009). Negative correlations involving the amygdala have been shown to 
be disrupted, and even reversed , in addiction and are thought to be linked 
with loss of impulse control (Xie et  al. ,  2011) .  We had hypothesized 
changes in cortico-amygdala connectivity due to dopamine depletion, as a 
probable cause for  the aversion changes observed in Chapter 5. The 
results of  this study suggest that,  changes in cortico-amygdala 
connectivity might indeed be the causality of aversion deficits .  
NaBu treatment was able to improve some of the lost positive 
correlations with respect to motor and sensory motor cortices. However, 
in was ineffective in mending the changes in negative correlations.  
Hence, a more extensive seed based or partial correlation analysis of the 
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data with a higher number of regions of interest might be able to 
delineate the pathway of NaBu treatment effect.  
Conclusion 
 We observed significant changes in the brain network as a result of  
dopamine lesions. The observations of loss of negative correlations of 
amygdala and increased basal -ganglia striatal connectivity are  accordance 
with the observations in addicts and various disease stated including PD .  
More extensive analysis is needed to predict how NaBu is  effective in 





































































































































Figure 60: Between group resting state correlation comparisons 
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Chapter 8.  Comprehensive summary 
Parkinson‘s disease (PD) is a chronic, progressive, neurodegenerative 
disorder, with no known exact  causes and no known cure .  Predominantly 
thought of as a motor disorder of the elderly, PD has also been known to 
have young and juvenile onsets starting by as early as 20 years of  age.  
With 1 million patients and $10.8 bil lion annual cost in the US alone, PD 
is the second most common neurodegenerative disorder (Chen, 2010; 
Parkinson'sDiseaseFoundation,  Accessed 2011) .  Most of the PD cases are 
thought to be idiopathic, but a combination of gen etic mutations and 
exposure to environmental toxins are implicated in increasing an 
individual‘s risk factor to this disease. Ever since it  was first identif ied by 
Dr. James Parkinson‘s in the 1817 as ‗shaking palsy‘,  PD is  sti ll  c linically 
diagnosed based on presence of motor symptoms. PD  has a significant 
impact on quality of li fe of the patients, as well  as,  the caregivers and 
family members.  
PD is predominantly thought of as  a movement disorder .  However,  a  
variety of co-morbid non-motor symptoms are also reported in the PD 
patients including but not l imited to depression, memory and executive 
function deficits,  changes in sense of smell,  deficits in recognition of 
various emotions and sleep disturbances. At the time of diagnosis,  the PD 
pathology has shown to have irreversibly damaged the substantia nigra 
neurons by as much as 50% and reduced the striatal dopamine by as much 
as 80%. In fact,  the predicted pre -diagnosis phase is thought to date back 
5-20 years (Gaig and Tolosa, 2009; Hawkes et al. ,  2010) . In the years 
prior to the onset of motor symptoms and clinical diagnosis,  patients 
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report a gamut of subtle non-motor deficits,  which if  quantified correctly,  
might provide us with the markers for early detection. However, the 
problem is that  these early signs are only apparent when the clinical  
diagnosis  is made.   
There were two overall goals of this study. First goal was to develop a 
rat model of PD that would successfully mimic the pre -clinical (or pre-
motor) stages of  PD along with delayed onset of  motor deficits.  The 
second goal was to characterize this model with behavioral and imaging 
experiment in order to develop pre -clinical markers for early detection of 
PD. Such a model would also facilit ate the development and testing of 
potential treatment strategies for the non -motor PD symptoms.  
Less than 20% of the PD cases are known to be linked to genetic 
mutations; and environmental toxins are thought to play a major role in 
the PD pathology (Caudle and Zhang, 2009; Tanner,  2010) . Therefore,  the 
primary focus of this research was on environmental appr oaches to PD 
symptoms and the neuropathology, as manifested in animal models  
exposed to the neurotoxin 6-hydroxy dopamine (6-OHDA). This 
neurotoxin is a dopamine analog, sharing some structural similarities  
with dopamine. It  is easily taken up by dopamine transporters and known 
to cause oxidative stress, mitochondrial  damage and neuro -inflamation 
(Na et al. ,  2010; Schober, 2004) . These effects are very similar to the PD 
etiology in that  similar  observation have been made in postmortem 
studies in PD patients (Gaig and Tolosa, 2009) . When injected into the 
striatum, 6-OHDA causes local reduction of dopamine conte nt in the 
striatum and retrograde degeneration of dopamine cells  in the SN 
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(Blandini  et al. ,  2007; Fleming et al. ,  2005; Yuan et al. ,  2005) . These 
lesions are progressive in nature and result in lower le vels of dopamine 
cell loss over a period of several weeks post the insult (Sauer and Oertel,  
1994). This facilitates the testing of potentially neuroprotective 
treatments in a time dependent manner, which is especially relevant to 
clinical  treatment regimens (Lindholm et  al . ,  2007) . Double and bilateral  
lesions of the striatum with 6-OHDA have shown to produce long lasting 
dopamine loss without compensatory effects weeks afte r the infusion(Ben 
et al. ,  1999). Our 6-OHDA lesioning protocol included 2-step bilateral 
lesions of the striatum, where the rats received 10ug of  6 -OHDA in 1ul of  
vehicle on day 1 and received 2ug of 6 -OHDA on day 3. The dopamine loss 
in CPu and dopamine cell depletion in SN of the 6 -OHDA lesioned rats,  at 
3 weeks post lesion, was determined to be 27% and 23%, respectively. 
This depletion was lower than the reports of 80% striatal loss of 
dopamine and 50% dopamine cell loss in the SN in PD patients at the 
time of onset of motor symptoms. The 6 -OHDA lesioned rats,  at 3 weeks 
post lesion time-point, neither exhibited any motor deficits in 
spontaneous locomotion, nor did they have any balance deficits  in the 
elevated beam walk test as compared to controls.  The 3WKPD rats,  also 
did not exhibit any changes in gait,  during the extensive gait analysis  
using DigiGait system. However,  PD -like gait was observed at 4 weeks 
post 6-OHDA lesions, and a trend towards development of similar deficits  
was noted at week 3.   
Among the reported non-motor deficits in PD, we tested our rat model 
for changes in aversion and changes in executive function.  The aversion 
behavior studies showed that,  there was significantly lower arousal to the 
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aversive BA odor  in the 3WKPD group, compared to the sham and control 
groups. Sham lesioned and control rats also exhibited equivalent 
avoidance of the aversive butyric acid smell as exhibited by lower time 
spent in the area with the BA odor in the avoidance behavior test.  
However, the 3WKPD rats did not exhibit a similar avoidance. Increased 
time spent with the aversive odor by the 3WKPD group implied a 
diminished avoidance compared to the sham group. These results are in 
agreement with observations noted in early stages of human PD, where 
PD patients exposed to aversive pictures exhibit blun ted reactivity and 
report less arousal as compared to controls,  despite recognizing the 
negative/aversive nature of those pictures (Bowers et  al . ,  2006; 
Sprengelmeyer et al. ,  2003) .  
One of the possible explanations of lower grooming and lower avoidance 
was that,  the PD rats  fai led to  smell the aversive odor as olfactory deficits  
are common in pre-motor PD. However, the lack of difference in the 
exploratory behavior between the groups in the arousal and avoidance 
behavior tests,  along with equivalent  BOLD activation of the olfactory 
system in the fMRI study, did not support th at premise. Furthermore, it  
is important to note that hyposmia in the pre -motor phase of the PD in 
human studies has been reported as a selective deficit ,  which depends on 
the odor and concentration being tested, a nd not a uniform loss of 
olfaction across all the scents (Berendse and Ponsen, 2009; Ponsen et al. ,  
2004).  
Another possible consideration to address the behavioral defi cits in 
aversive behavior in the PD rat model was the role of brain regions which 
128 
 
process aversive stimuli including Insular cortex, Nucleus Accumbens and 
Amygdala complex.  Involvement of Insular cortex has been reported 
during aversion processing in human  (Jabbi et al. ,  2008; Small et al. ,  
2003; Sprengelmeyer et al. ,  1998) , as well as,  in rat studies (Desgranges 
et al. ,  2009). NAcc neurons are believed to be involved in attaching 
valance to a stimulus by either selective activation or inhibition of 
neurons (Carlezon and Thomas,  2009; Roitman et  al. ,  2005; Schoenbaum 
and Setlow, 2003) . We performed BOLD fMRI experiments on our rats in 
awake state during exposures to the same aversive smell.  Our results did 
not indicate any differences in the insular cortex activation between 
groups, which might have been a contributing factor to the observed 
deficits  in the behavioral responses.  This  result is  in accordance with the 
disease stage-dependent hypoperfusion of insular cortex observed in 
human PD patients where there is no significant difference between the 
controls and early PD patients. (Kikuchi et al. ,  2001)  We also observed 
equivalent positive BOLD activation in NAcc in controls,  shams and 
3WKPD rats,  without any significant group effect in  neuronal activation.  
However, the amygdala region, which is known to process emotions and 
generate the response cascade to stressful/aversive stimuli,  had an 
overall lower positive BOLD activation in PD. When selective nuclei in 
the amygdala, medial (MNA), basal (BNA), lateral (LNA) and central  
(CNA) nuclei,  were examined individually,  significantly lower BOLD 
activation was observed in the BNA, LNA and CNA of PD rats compared to 
both sham lesioned and control rats.  The amygdala complex comprises of 
a multi-level system that orchestrates both sensory input and output. In 
regards to olfaction,  the MNA is thought to receive inputs from accessory 
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olfactory bulb (Davern and Head, 2011) ; inhibition of  baso-lateral 
amygdala has been shown to result in impairment of  conditioned 
olfactory aversion (Desgranges et al. ,  2008); and CNA thought to mediate 
behavioral  response to aversive st imuli  (Finn et al. ,  2003) . Given the 
results of  our studies, we speculate that the MNA, which serves as the 
input to the amygdala complex, was functional in the PD rats while the 
BNA, LNA and CNA, which orchestrate the  response, were negatively  
impacted. Hence, it  appeared that the behavioral deficit,  exhibited by PD 
rats in our study, might have been a result of a deficit  in appropriate 
response generation due to a possible cortico -amygdalar dysfunction, and 
not due to an inability to process the aversive stimulus . Our results are in 
accordance with those by Bower‘s and colleagues who  have also reported 
blunted aversive reactivity among PD patients that was attributed to 
amygdalar dysfunction as a result of suppression of the amygdala by the 
cortical regions (Bowers et al . ,  2006) . Since the sham lesioned animals 
did not exhibit any arousal or avoidance deficits as compared to the 
control animals in the behavioral tests,  as well as,  in the functional MRI 
experiment; we conclude that the observed deficits in the 6 -OHDA 
administrated rats were not a result of  the stress of the surgery but of 
actual dopamine depletion.  
Executive functioning was tested in our rat model using a rat analog of 
the Wisconsin card sorting test used to test attentional set  shifting in 
humans. The test in rats is  called the ED/ID test,  and comprises of four 
tasks designed to test various aspects  of executive function including 
attention, rule acquisition, cognitive flexibility,  error correction and 
trouble shooting. The overall performance of the rats during the four 
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tasks involved in the ED/ID test was similar to the previous observations 
of progressively increasing difficulty lev els  while moving from SD to CD 
to ID to ED tasks. The control and the sham rats required a higher 
number of trials for completion of ID and ED tasks as compared to the 
first two tasks, though the difference was not significant for ID in 
controls.  The 3WKPD rats also had similar performance,  but needed 
significantly more trials in the ED task as compared to ID task. Their  
performance in the first 3 tasks was comparable to the performance by 
the control and the sham groups, implying a similar reward associati on,  
rule-learning and attentional-set formation in the three groups. But the 
3WKPD group was significantly less efficient  in the ED task, indicating a 
set-shifting specif ic  deficit.  These results were in accordance with 
previous observations in PD patients  where set-shifting specific deficits 
have been reported (Cools et  al. ,  2003; Owen et  al. ,  1992; Schneider, 
2006). The cognitive inflexibility,  as  depicted by a deficit  in the ED task,  
can be the result of two phenomena, deficits in revising the relevance of  
‗ initially relevant dimension‘,  and /or enhanced learnt irrelevance towards 
‗ initially irrelevant dimension‘,  leading to an inability to attend to the 
dimension previously learnt as irrelevant. Our study had the complete -
learnt irrelevance design in terms of the ED. Hence,  our rats did exhibit 
deficits in revising learnt irrelevance based on negative feedback they 
received after incorrect trials.  Our results were in agreement with those 
by Owen‘s group reporting more pronounced ED deficit  in PD patients in 
the case of shifting attention to a dimension previously learnt as  
irrelevant, hence enhanced learnt irrelevance being the contribu ting 
factor to the deficit  (Slabosz et al. ,  2006) . The observed ED deficit  in 
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3WKPD rats,  might be a result of an inability to learn new rules due to 
lowered dopamine levels disrupting PFC -striatal connectivity. This 
connectivity is hypothesized to be important for set shifting and is  
impacted in PD patients (Monchi et al. ,  2004) . Dopamine depletion has 
been shown to cause disruption of PFC -striatal connectivity, as well as,  
ED deficits in healthy controls  (Nagano-Saito et al. ,  2008).  Indeed, lack 
of similar deficits in sham lesioned rats,  support the hypothesis of 
dopamine depletion as a probable cause;  thus, eliminating the potential  
impact of stress of the lesioning process as a probable cause for the ED 
deficit.   
While shifting from CD to ID task, both the 3WKPD and sham lesioned 
groups needed significantly higher number of trials,  as compared to their  
own performance in the CD task. A similar significance was missing in the 
control group. Even though the ID performance was not significantly  
different between the groups, the within group comparisons suggest a 
weaker attentional-set formation in the sham and the 3WKPD groups due 
to the surgical procedure and irrespective of the dopamine depletion.  
Cingulate cortex lesions have shown to result in ID deficits in rats (Ng et  
al. ,  2007) without any ED deficits.  To our knowledge,  our rats did not 
have cingulate cortex lesions. This was also supported by the fact  that ,  
the deficits we observed were not in comparison with the controls,  as  
those observed by the Ng group, but were in comparison to the groups‘ 
own performances in the previous tasks. Additional research is needed to 




The performance of the 3WKPD+NaBu group in the ED task had 
significant improvement over the performance of the 3WK PD group, and 
was comparable to the performance by the control group. Hence, NaBu 
appeared to be effective in alleviating the deleterious effects  of 6-OHDA. 
In addition, the 3WKPD+NaBu rats,  as they performed SD, CD and ID 
tasks, were able to focus increas ing amount of attention on the IRD and 
completely ignore IID. Hence, the NaBu treatment might have additional 
cognitive enhancing effects over 3WKPD group, as reflected by significant 
group by task interaction. Additional experimentation is needed to 
confirm this hypothesis,  but was outside the scope of this thesis.  
However, results of  this study pointed towards HDACis as a promising 
treatment option for cognitive deficits in PD.  
Seed based RS connectivity, was performed in our rats with seeds  based 
on localized voxels  with high z-score ICA components within various 
regions of interests  (ROIs) (Roy et al. ,  2009) . Even though, the seeds 
only covered a part of the ROI that they belonged to, the final 
connectivity map had a good representation of the entire  ROI. We 
contend that,  this technique might indeed be a better  technique of seed 
selection than pure anatomical map based seeds. The control rats  in this 
study exhibited specific connectivity patterns based on seeds similar to 
those reported previously by our lab (Zhang et al. ,  2010) . We also 
observed signific ant RS connectivity  alterations in the 3WKPD group .  
One of the prominent changes observed in this study was the increased 
overall connectivity of the motor cortex , which was in accordance with 
the increased motor cortex connectivity observations in human PD 
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patients (Gatev et al . ,  2006; Wu et al. ,  2010) . Similarly, we also observed 
an increase in CPu connectivity with prefrontal cortices, cingulate cortex,  
and hypothalamus in the 3WKPD rats compared to the controls.  Kwak and 
group report a significant increase i n striatal connectivity with medial,  
inferior and orbital frontal  gyruses, as well as,  anterior cingulate cortex 
in unmedicated early-stage PD patients as compared to age matched 
controls (Kwak et al . ,  2010) . Hence, our results parallel observations  in 
human PD. The same study by Kwak group, also reported a reduction in 
this hyper-connectivity with L-DOPA treatment. L-dopa is  known to 
increase dopamine levels in brain. Basal ganglia activity is modulated by 
dopamine,  and reduction in dopamine levels result  in oscil latory firing of 
neurons in the basal ganglia –  thalamocortical circuitry, leading to 
increased synchronization between those regions (Gatev et  al. ,  2006) . 
Gatev has also hypothesized that the tremors observed in PD might be 
linked to this increase in basal ganglia oscillations and neuronal 
synchrony (Gatev et  al. ,  2006) . This is  interesting because, even though 
our 3WKPD rats did not exhibit any significant motor deficits,  they 
exhibited a trend towards development of shuffling gait as observed in PD 
patients, and the rats at 4 week post 6-OHDA lesions, indeed exhibited 
gait similar to PD. Hence, our observations of increased CPu and Motor 
cortex connectivity might be indicative of oncoming onset of motor 
deficits.  
Another major difference observed between the control and the PD 
group, was the loss of negative correlation between the amygdala and 
CPu, motor cortex, PFC, cingulate cortex and olfactory bulb in the PD 
group. Significant negative correlation has been reported between the 
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baso-lateral amygdala and prefrontal cortex in healt hy subjects (Roy et  
al. ,  2009). These regions are thought to be important in response 
generation and in facilitation of   attention to salient  stimuli  (Roy et al. ,  
2009). Negative correlations involving the amygdala have been shown to 
be disrupted, and even reversed, in addiction and are thought to be linked 
with loss of impulse control (Xie et  al. ,  2011) .  We had hypothesized 
changes in cortico-amygdala connectivity due to dopamine depletion, as a 
probable cause for  the aversion changes observed in Chapter 5. The 
results of  this study suggest that,  changes in cortico -amygdala 
connectivity might indeed sub-serve the aversion deficits.  
Based on the extended PD stages proposed by Braak group (Hawkes et  
al. ,  2010), PD patients at  the late Braak stage 2 or at beginning of Braak 
stage 3, do not have any significant motor symptoms, but thought to have 
the SN pathology and striatal dopamine depletion. In addition, amygdalar  
pathology is also thought to start at these stages. Hence, we contend that  
this model might in fact be mimicking the symptomology of early Braak 
stage 3 or late Braak stage 2 PD, and the cognitive and aversion deficits  
observed, might indeed be present in these stages.   
We have also shown that  NaBu treatment  was effective in treating extra -
dimensional set shifting cognitive deficits.   NaBu was also able to 
improve upon some of the lost positive correlat ions with respect to motor 
and sensory motor cortices  which might underlie the motor deficits in PD . 
Given that  the drugs from HDACi family of drugs are  well-tolerated by 
humans (Hoshino and Matsubara, 2010; Liu et al. ,  2006) , this treatment 
shows high translational validity.  
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Our RS connectivity  study fai led to delineate how NaBu was able to 
improve cognitive deficits.  A more extensive seed based or partial  
correlation analysis  of the data with a higher number of regions of  
interest might be able to delineate the pathway of NaBu treatment effect.  
Global impact 
Pre-clinical markers, if  developed, can lead to the early diagnosis of PD 
in individuals  predisposed to this disease due to genealogy or proximity 
to toxic environments. Early det ection can enable us to devise strategies 
to prevent further damage.   
  Findings of this research suggest that our model of pre -motor stage PD 
is a very high face validity rat model of late Braak stage 2 or early 
Braak stage 3 PD. These are the pre -motor stages of PD and hence, can 
be used for further research into non -motor symptoms of PD.  
  PD patients, with as much as 80% dopamine depletion in the striatum, 
are stil l  not clinically diagnosed  because they do not exhibit  any motor 
symptoms. However , we have shown that a combination of  reduced 
aversion, extra-dimensional set shifting deficit,  increased RS motor 
cortex and striatal connectivity and lack of negative RS connectivity of 
the amygdala could be a present in patients with as litt le as 30% 
striatal dopamine depletion. Hence, these could be viable biomarkers 
for early detection of  PD.  
  Sodium butyrate treatment, tested in the cognitive deficit  study, was 
able to ameliorate the extra -dimensional set shift ing deficit  observed 
in this model.  This treatment als o improved the attentional set  
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formation. Our results,  along with the prior reports of anti -depressant 
and neuroprotective effects of this drug, point towards a possible 
treatment strategy for the non -motor deficits of  PD, which are not 




Chapter 9. Future direction 
We have successfully demonstrated that  our model exhibits some of the 
non-motor symptoms of Parkinson‘s disease. Although significant steps 
have been made with  this study, more work needs to be done to reach the  
final goal of early detection of Parkinson‘s disease and t reating its non-
motor symptoms. Outlined below are possible studies that  have been 
identified that  will help us move closer to  the above mentioned goal.  
1.  We performed all  the studies at three  weeks post 6-OHDA 
infusions, given that  it  was the pre-motor time-point. Our observations of  
dopamine depletion, aversive and cognitive deficits,  as  well as,  RS 
connectivity changes, were all performed at this time -point.  
Immunohistochemistry studies at 2 week and 4 week time points would 
give an insight into the progression of  these lesions.   
2.  Addition of brain regions such as olfactory bulb, PFC and medial 
forebrain bundle would add to the knowledge of spread of the 6 -OHDA 
lesions.  
3.  Adding similar t ime-points in the aversion, cognitive and RS 
connectivity studies, would allow observation of manifestation and 
progression of the behavioral deficits and co-morbid connectivity changes 
in the brain.  
4.  Our aversion study focused on unconditioned olfactory aversion 
changes. Future studies with aversion in other sensory modalities,  such 
as taste aversion, would help in generalization of this deficit .  Also, 
testing conditioned aversion,  might give added insight into the pathology.  
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5.  The cognitive inflexibility,  as depicted by  deficit  in the ED task, can 
be a result of two phenomena, deficits in revising the relevance of IRD, 
and enhanced learnt irrelevance towards IID, leading to inability to 
attend to dimension previously learnt as irrelevant.  Our ED/ID study 
design onely tested for learnt-irrelevance. Hence,  additional testing with 
a completely novel dimension as the relevant dimension during the ED 
task would be able to delineate the exact  cause of the observed ED deficit.  
6.  Some of the preliminary work we  have done is indicat ive of  
additional emotional changes in apathy and depression. Depression was 
tested using forced swim test,  where the 3WKPD rats exhibited increased 
immobility,  indicative of depression. Apathy was tested using novel 
object recognition test and sucrose pre ference test.  Though there was no 
significant difference between the sucrose consumption by the test  
groups, we observed significantly lower exploration of the novel object  by 
the 3WKPD group as compared to the control group. This observation 
points towards possible increased apathy in the 3WKPD rats.  We had also 
tested olfaction, where behavior of  the 3WKPD rats points towards 
selective olfactory deficits .  All of these tests would add to the face 
validity of  this model.  
7.  The RS connectivity changes ,  observed in our rat model of PD , have 
also been reported in early PD patients. Th e human reports also point out  
that the some of these connectivity changes are mitigated by L -DOPA 
treatment. Performing RS connectivity and the gait analysis studies with 
an additional L-DOPA treated group would be useful in determining the 
predictive validity of  this model.   
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8.  Sodium butyrate treatment was not just useful in alleviating the ED 
deficits observed in our 3WKPD rats,  but it  also improved the attentional 
set formation in the treatment group. But the RS connectivity study was 
unable to delineate the pathway of NaBu treatment effect.  Hence, 
additional behavioral studies testing attention and RS analysis with more 
seed regions are needed to test the exact  effect of  NaBu. Addin g a NaBu 
treatment group to immunohistochemistry study will help in 
determination of whether the treatment was effective in preventing the 
deleterious effects of 6-OHDA. NaBu has also been proven effective in 
treating depression and has been thought to hav e neuro-protective 
effects.  It  presents a promising treatment strategy for PD. Additional 
testing in other deficits would help determine this possibility.  
9.  We have used functional MRI to look at changes in functional 
responses of the brain. Adding Magnetic resonance spectroscopy to the 
list of studies will help detection of  changes in brain metabolite as a 
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